

Io sottoscritto **Angelo Paolo Dei Tos** consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76 del D.P.R. 445/2000 e successive modificazioni ed integrazioni per le ipotesi di falsità in atti e dichiarazioni mendaci, dichiara che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità.

**INFORMAZIONI PERSONALI ANGELO PAOLO DEI TOS****ESPERIENZA  
PROFESSIONALE**

- 
- 13/10/2022 (incarico per 9 mesi)-  
alla data attuale **Direttore ad interim della U.O.C. Microbiologia e Virologia**  
Azienda Ospedale Università Padova (Italia)
- 01/10/2022–alla data attuale **Presidente del Consiglio della Scuola di Medicina e Chirurgia per il triennio  
accademico 2022-25**  
Università degli Studi di Padova (Italia)
- 08/11/2021–alla data attuale **Direttore del Dipartimento Funzionale Interaziendale di Anatomia Patologica**  
Azienda Ospedale Università Padova (Italia), Azienda ULSS 5 Polesana, Azienda ULSS 6  
Euganea, Istituto Oncologico Veneto IRCCS
- 01/10/2021–alla data attuale **Direttore del Dipartimento DIDAS -SERVIZI DI DIAGNOSTICA INTEGRATA**  
Azienda Ospedale Università Padova (Italia)
- 01/10/2019–alla data attuale **Direttore del Dipartimento funzionale di Anatomia Patologica**  
Azienda Ospedale Università Padova (Italia)
- 04/05/2021–alla data attuale **Rappresentante ERN EURACAN (European Reference Network on Rare Adult  
Cancer) per Azienda Ospedale Università Padova**  
Azienda Ospedale Università Padova
- 07/01/2021–alla data attuale **Coordinatore della Rete Anatomie Patologiche del Veneto (RAP).**  
Regione Veneto
- 2016–alla data attuale **Professore Ordinario di Anatomia Patologica, Dipartimento di Medicina**  
Università degli Studi di Padova (Italia)
- 01/01/2010–31/12/2016 **Direttore del Dipartimento Funzionale di Oncologia**  
Azienda ULSS 2 Marca Trevigiana (ex ULSS 9), Treviso (Italia)
- 2013–2015 **Direttore Scientifico del Registro Tumori della Regione Veneto**
- 12/12/2002–31/05/2016 **Direttore UOC di Anatomia Patologica dell'Ospedale Civile Ca' Foncello**  
AULSS 2 Marca Trevigiana (ex ULSS 9), Treviso (Italia)

- 2008–31/12/2009 **Direttore Dipartimento di Patologia Clinica**  
Azienda ULSS 2 Marca Trevigiana (ex ULSS 9), Treviso (Italia)
- 20/10/1994–11/12/2002 **Dirigente Medico di I° Livello, del Servizio di Anatomia Patologica dell'Ospedale Ca' Foncello**  
Azienda ULSS 2 Marca Trevigiana (ex ULSS 9), Treviso (Italia)
- 01/05/1993–19/10/1994 **Aiuto di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile**  
Azienda ULSS 2 Marca Trevigiana (ex ULSS 9), Conegliano (TV) (Italia)
- 01/03/1992–30/04/1993 **Aiuto di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile**  
Azienda ULSS 1 Dolomiti, Feltre (BL) (Italia)
- 05/08/1988–28/02/1992 **Assistente di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile**  
Azienda ULSS 2 Marca Trevigiana (ex ULSS 9), Conegliano (TV) (Italia)
- 22/07/1987–04/08/1998 **Ufficiale Medico del Corpo di Sanità dell'Esercito**  
**Coordinatore diagnostica patologica Rete Nazionale Tumori Rari**

## ISTRUZIONE E FORMAZIONE

2005 **Specializzazione in Dermatologia**  
Università degli Studi di Trieste (Italia)

Partecipazione ad Iniziative di Aggiornamento e Qualificazione e Stage teorico pratici presso istituzioni prevalentemente estere, tra le quali il St. Thomas's University Hospital di Londra, il Brigham and Women's Hospital, Harvard Medical School di Boston, e la Mayo Clinic di Rochester.

1985–1989 **Specializzazione in Anatomia Patologica**  
Università degli Studi di Padova (Italia)

1980–1985 **Laurea in Medicina e Chirurgia con votazione di 110/110 e lode**  
Università degli Studi di Padova (Italia)

1976–1980 **Diploma di Liceo scientifico**  
Liceo Scientifico Statale "Marcantonio Flaminio", Vittorio Veneto (TV) (Italia)

## COMPETENZE PERSONALI

Lingua madre italiano

Lingue straniere	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C2	C2	C2	C2	C2

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato  
Quadro Comune Europeo di Riferimento delle Lingue - Scheda per l'autovalutazione

Competenze professionali Valutatore e responsabile di Sistemi Qualità in Sanità.

Patente di guida B

## ULTERIORI INFORMAZIONI

## ATTIVITA' DIDATTICA

- Professore Ordinario di Anatomia Patologica, Università degli Studi di Padova. Dall'anno accademico AA 2016/17 ad oggi
- Professore a contratto di Anatomia Patologica, Facoltà di Medicina, Università di Padova, Sezione di Treviso. AA. 2014-2016
- Professore a Contratto di Tecnica e Diagnostica Immunoistochimica, Scuola di Specializzazione in Anatomia Patologica, Università di Padova. 2001-2010
- Professore a contratto di Genetica. Scuola di specializzazione in Anatomia Patologica. Università di Sassari. 1997-2006.
- Professore a contratto di fisiopatologia generale. Corso di Laurea in Fisioterapia. Università di Padova. 1998-2010.
- Professore a contratto di Microbiologia medica. Diploma di Fisioterapia. Università di Padova. 1997-1998.
- Titolare del corso breve "Small Round Cell Neoplasms of Soft Tissues: A Diagnostic Approach" presso la Divisione Americana e Canadese dell'International Academy of Pathology (2001-2005).
- Docente di Patologia Generale ed Igiene, Scuola per terapisti della Riabilitazione, La Nostra Famiglia, Conegliano. 1989-1997

ORGANIZZATORE EVENTI  
FORMATIVI:

- "Diagnostic Histopathology of Soft Tissue Tumours". Conegliano. 12-13 Giugno 1992. In collaborazione con St-Thomas & Guy's Hospital Londra..
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 13-14 aprile 1996. In collaborazione con Harvard Medical School, Boston USA.
- "Diagnostic Histopathology of Tumors and Tumor-like Condition of Bone". Treviso, 2-3 ottobre 1997. In collaborazione con Mayo Clinic Medical Laboratories.
- "Diagnostic Histopathology of Tumors of the Nervous System". Treviso, 21-22 maggio 1998. In collaborazione con Mayo Clinic Medical Laboratories.
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 20-21 maggio 1999. In collaborazione con Harvard Medical School, Boston USA.
- "Diagnostic Histopathology of Inflammatory Skin Diseases". Treviso, 22-23 maggio 2000. In collaborazione con Harvard Medical School, Boston USA.
- "Diagnostic Histopathology of Tumors and Tumor-like Condition of Bone". Treviso, 18-19 maggio 2001. In collaborazione con Mayo Clinic Medical Laboratories. (11 crediti formativi ECM)
- "Diagnostic Immunohistochemistry". Treviso, 11-12 ottobre 2001. (11 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 18-19 aprile 2002. In collaborazione con Harvard Medical School, Boston USA. (14 crediti formativi ECM).
- "Riunione autunnale IAP/SIAPEC". Treviso, 27-29 ottobre 2002. (12 crediti formativi ECM).
- "Diagnostic Histopathology of Malignant Lymphomas". Treviso 10-11 aprile 2003. In collaborazione con il Queen Elizabeth Hospital, Kowloon, Hong Kong.
- "Diagnostic Histopathology of Non-neoplastic and neoplastic Lung Diseases". Treviso, 28-29 ottobre 2004. In collaborazione con Mayo Clinic Medical Laboratories. (11 crediti formativi ECM)
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 5-6 maggio 2005. In collaborazione con Harvard Medical School, Boston USA (12 crediti formativi ECM).
- "Diagnostic Immunohistochemistry". Treviso, 26-27 ottobre 2005. (11 crediti formativi ECM)
- International Course on Surgical Pathology. Joint event cosponsored by Mayo Clinic. Treviso, 2-5 maggio 2006.
- ESMO International Symposium on GIST and Sarcomas. Milano, 15-18 giugno 2006
- Update on Surgical Pathology. Treviso 8-9 novembre 2006. In collaborazione con il Queen Elizabeth Hospital, Kowloon, Hong Kong. (7 crediti formativi ECM)

- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, 29 novembre-2 dicembre 2006 (36 crediti formativi ECM).
- "Diagnostic Histopathology of Tumors of the Uterus and Ovary". Treviso, 26-27 aprile 2007. In collaborazione con Harvard Medical School, Boston USA (10 crediti formativi ECM).
- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, 14 -17 maggio 2007 (36 crediti formativi ECM).
- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, 14 -17 maggio 2008 (36 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 8-9 maggio 2008. In collaborazione con Harvard Medical School, Boston USA (12 crediti formativi ECM).
- ESMO International Symposium on GIST and Sarcomas. Milano, 13-14 maggio 2008
- "Diagnostic Histopathology of neoplastic and nonneoplastic conditions of GI Tract". Treviso, Settembre 2008. In collaborazione con Cleveland Clinic, Cleveland USA (10 crediti formativi ECM).
- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, April 2009 (36 crediti formativi ECM).
- ESMO International Symposium on GIST and Sarcomas. Milano, Marzo 2010
- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, Maggio 2010 (36 crediti formativi ECM).
- "Diagnostic Surgical Pathology". Treviso, 9-11 dicembre 2010. In collaborazione con la Cleveland Clinic, Cleveland USA (12 crediti formativi ECM).
- Corso residenziale su patologia mesenchimale "I.D.E.A". Treviso, Aprile 2011 (36 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 8-9 maggio 2011. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
- ESMO International Symposium on GIST and Sarcomas. Milano, 7-10 Marzo 2012
- "Diagnostic Histopathology of GYN Tumors". Treviso, 29-30 Maggio 2012. In collaboration with Harvard Medical School, Boston USA (9 crediti formativi ECM).
- "Diagnostic Histopathology of Breast Tumors". Treviso, 29-30 Novembre 2012. In collaboration with Harvard Medical School, Boston USA (9 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 8-9 maggio 2013. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
- ESMO International Symposium on GIST and Sarcomas. Milan, 18-19 March 2014
- "Diagnostic Histopathology of Gynecologic tumors". Treviso, 27-28 novembre 2014. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 7-8 maggio 2015. In collaborazione con Harvard Medical School, Boston USA 12 crediti formativi ECM).
- "AACR Meeting, Basic Science of Sarcomas". Salt Lake City, USA, 3rd -4 th November, 2015
- "20th Connective Tissue Oncologic Society Annual Meeting", Salt Lake City, USA, 5th -7 th November, 2015.
- "Diagnostic Histopathology of Tumors of Central Nervous Syatem". Treviso, October 2016. In collaboration with Mayo Clinic (12 crediti formativi ECM).
- "Diagnostic Histopathology of Soft Tissue Tumors". Treviso, 12-13 ottobre 2017. In collaborazione con Harvard Medical School, Boston USA 12 crediti formativi ECM).

#### PREMI E RICONOSCIMENTI

- Premio Europeo "Giovani Medici" CRS AMPLIFON - 1988
- Premio Lega Italiana per la Lotta Contro i Tumori -1992
- Roger Cotton Histopathology prize - 2010

#### AFFILIAZIONE A SOCIETA' SCIENTIFICHE

- United States and Canadian Academy of Pathology (Membro del corpo docente quinquennio 2001-2005 e 2012-2014) dal 1994.

- International Society of Bone and Soft Tissue Pathology (Past President).
- European Society of Pathology (Chairman del Gruppo operativo di studio delle neoplasie mesenchimali) dal 1999
- Connective Tissue Oncologic Society: Past President
- Società Italiana di Anatomia Patologica e Citodiagnostica (membro del Consiglio direttivo nazionale – trienni 2002-2004 e 2005-2007).
- Arthur Purdy Stout Society of Surgical Pathology (Council Member) dal 2000
- International Skeletal Society dal 1999
- European Society of Medical Oncology: faculty member 2006-2015. Media Ambassador (2010)

#### EDITORIAL BOARD

- Editor in Chief: “Clinical Sarcoma Research”
- “American Journal of Clinical Pathology”
- “Journal of Pathology”
- “Advances in Anatomic Pathology”
- “Journal of Clinical pathology”
- “Applied immunohistochemistry and molecular morphology”
- “Pathologica”
- “Seminars in Diagnostic Pathology”
- “Virchow Archiv”
- “Surgical Oncology” – Section Editor

#### PROGETTI DI RICERCA

- Chairman “Dissemination and spread of excellence program” del progetto quadro CEE KP6: Eurobonet (Finanziamento quinquennale di un network europeo di eccellenza nella diagnosi e ricerca della patologia tumori ossea (finanziamento: € 12.600.000,00).
- Chairman dello studio retrospettivo nazionale sui Tumori Gastrointestinali “Register”
- Chairman WP4 progetto europeo “Rarecare”
- Titolare dell’analisi centralizzata dell’espressione di EGFR nel carcinoma avanzato del colon trattato con anticorpi monoclonali umanizzati contro EGFR (cetuximab).
- Chairman “Dissemination and spread of excellence program” del progetto quadro CEE KP7: EUROSARC
- Chairman Transverse Task Force “Pathology” European Reference Network “EURACAN”.

#### ATTIVITA' DI RICERCA

- Svolge dal 1996 attività di consulenza diagnostica su casi di patologia oncologica mesenchimale e su tumori rari provenienti da istituzioni italiane ed estere e coordina la diagnostica patologica della Rete Nazionale Tumori Rari.
- Membro della “faculty” WHO per la classificazione dei tumori mesenchimali (dal 2000).

**PUBBLICAZIONI** Autore di 395 pubblicazioni scientifiche “peer reviewed” in maggioranza edite in riviste specialistiche di rilevanza internazionale.

**1988**

1. Bernardi M, Della Libera D, Dei Tos AP. Descrizione di un caso di mesotelioma pleurico insorto in un soggetto a basso rischio specifico. **Acta Oncol 1988; 9:59-62;**

**1989**

2.“Lo sviluppo embriologico e fetale della laringe”. Carlon G, Bertondini A, Della Libera D, Dei Tos AP. **Carlton G, Serafini I. Il Carcinoma Sopraglottico. Padova Piccin, 1989:71-81;**

**1990**

3. Carlon G, Della Libera D, Dei Tos AP. A whole organ sectioning method for histologic examination of laryngeal and hypopharyngeal specimens. **Sacristan T (ed) Otorhino- laryngology, Head and Neck Surgery. 1990; 2367-2371;**

4. Serafini I, Ghirardo R, Pazzoia T, Bittesini L, Della Libera D, Dei Tos AP. Advanced glottic carcinoma: treatment, pathology and follow-up”. **Sacristan T (ed) Otorhinolaryngology, Head and Neck Surgery, 1990; 2461-3.**

**1991**

5. Dei Tos AP. “Il carcinoma squamoso verrucoso della glottide”. **Serafini I (ed) Il carcinoma glottico. Piccin Padova 1991.**

6. Bittesini L, Dei Tos AP. Anatomia della regione glottica. in Serafini I (ed) Il carcinoma glottico. **Piccin Padova, 1991.**

7. Della Libera D, Dei Tos AP. Il carcinoma glottico ad estensione sopraglottica. **Serafini I (ed) Il carcinoma glottico. Piccin Padova, 1991.**

8. Bittesini L. Dei Tos AP. Proposta per un pT clinicamente orientato. Serafini I (ed) Il carcinoma glottico. **Piccin Padova, 1991.**

9. Serafini I, Lucioni M, Bittesini L, Dei Tos AP. Sul trattamento del carcinoma adenoido-cistico laringeo. **Acta Otorhinol Ital 1991, 11:13-24.**

**1992**

10. Bittesini L, Dei Tos AP, Fletcher CDM. Malignant melanoma showing rhabdoid differentiation. Further evidence of a non- specific histologic pattern. **Histopathology 1992;20:167-170.**

11. Dei Tos AP, et al. Aspiration Biopsy cytology of malignant papillary neoplasms of the breast. **Diagn Cytopathol, 1992;8:580-584.**

12. Ghirardo R, Lucioni M, Dei Tos AP, Bittesini L. Chondrosarcoma of the larynx: a case report with clinicopathologic correlation. In G. Motta (ed). **The new frontiers of ORL in Europe. Monduzzi, 1992, 411- 414.**

## 1993

13. Dei Tos AP, et al. p53 expression in non neoplastic lesions and benign and malignant neoplasms of soft tissue". **Histopathology**, 1993;22:45- 50.

14. Dei Tos AP, et al. Cytodiagnosis of primitive carcinoid tumor of the wirsung duct. **Diagn Cytopathol** 1993;9:471-474.

15. Dei Tos AP, et al. KP1 expression in benign neural tumours. **Histopathology** 1993;23:185- 187.

16. Doglioni C, Laurino L, Dei Tos AP, et al. Pancreatic (acinar) metaplasia of the gastric mucosa. An immunocytochemical and ultrastructural study. **Am J Surg Pathol** 1993;17:1134-1143.

## 1994

17. Dei Tos AP, et al. Fibroepithelial tumour of the breast with digital fibroma-like stromal component. A morphological, immunocytochemical and ultrastructural analysys. **Am J Surg Pathol** 1994;18:296-301.

18. Dei Tos AP. Aspiration biopsy cytology of malignant papillary breast neoplasms. **Am Soc Clin Pathol Check Sample Series** 1994, C-94-10.

19. Doglioni C, Dei Tos AP, et al. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinico-pathologic correlates, with particular reference oestrogen receptor status". **Virchows Arch (A)** 1994;424:47-51.

20. Dei Tos AP, et al. UV- induced p53 mutations in atypical fibroxanthoma". **Am J Pathol** 1994;145:11-17.

21. Dei Tos AP, et al. Aspiration biopsy cytology of tubular carcinoma of the breast. **Diagn Cytopathol** 1994; 11:146-150.

22. Dei Tos AP, et al. Spindle cell liposarcoma: a hitherto unrecognized variant of well- differentiated liposarcoma: analysis of six cases".. **Am J Surg Pathol** 1994; 18:913-921.

23. Mentzel T, Dei Tos AP, Fletcher CDM. Perineurioma (storiform perineural fibroma): clinicopathological analysis of four cases. **Histopathology** 1994; 25:261-267.

## 1995

24. Dei Tos AP, et al. Aspiration biopsy cytology of intranodal myofibroblastoma. **Diagn Cytopathol** 1995; 13:134-138.

25. Dei Tos AP, et al. Fibroepithelial tumor. Author's reply. **Am J Surg Pathol** 1995; 19:730-732.

26. Dei Tos AP, et al. Giant cell angiofibroma. A distinctive orbital tumor in adults. **Am J Surg Pathol** 1995; 1286-1293.

27. Dei Tos AP, et al. Immunohistochemical demonstration of glycoprotein p30/32MIC2 (CD99) in synovial sarcoma. A potential cause of diagnostic confusion. **Appl Immunohistochem** 1995; 3:168-173.

1996

28. Dei Tos AP, et al. Tumor suppressor genes and related molecules in leiomyosarcoma". **Am J Pathol 1996; 148:1037-1045.**

29. Dei Tos AP, et al. S-100 protein staining in liposarcoma. Its diagnostic utility in the high grade myxoid (round cell) variant. **Appl Immunohistochem 1996; 4:95-101.**

30. "Dei Tos AP et al S-100 protein reactivity in synovial sarcomas. A potentially frequent diagnostic pitfall. Immunohistochemical analysis of 100 cases. **Appl Immunohistochem 1996; 4:167-175.**

31. Doglioni C, Dei Tos AP, et al. Calretinin: a novel immunocytochemical marker for mesothelioma". **Am J Surg Pathol 1996; 20:1037-1046.**

32. Dei Tos AP. Uterine smooth muscle neoplasms: a diagnostic dilemma. **Pathologica 1996; 88:141-143.**

33. Dei Tos AP. Liposarcoma: controversies and conceptual problems. Editorial. **Pathologica 1996; 88: 467-471.**

34. Dei Tos AP. Malignant fibrous histiocytoma: a vanishing entity? **Pathologica 1996; 88:522-524.**

1997

35. Cummings OW, Ulbright TM, Young RH, Dei Tos AP, Fletcher CDM, Hull MR. Desmoplastic small round cell tumors of the paratesticular region. A report of six cases". **Am J Surg Pathol 1997; 21:219-225.**

36. Dei Tos AP, et al. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. **J Pathol 1997; 181:8-13.**

37. G. bcl-2 expression in pleural and extrapleural solitary fibrous tumor. Chilosi M, Facchetti F, Dei Tos AP, et al. **J Pathol 1997, 181: 171-181.**

38. Mentzel T, Mazzoleni G, Dei Tos AP, Fletcher CDM. Kaposiform hemangioendothelioma in adults: clinicopathological and immunohistochemical analysis of three cases. **Am J Clin Pathol 1997; 108:450-455.**

39. Dei Tos AP et al. Extraskelatal myxoid chondrosarcoma: an immunohistochemical reappraisal of 39 cases. **Appl Immunohistochem 1997; 5:73-77.**

40. Dei Tos AP, et al. The role of cytogenetics in the classification of soft tissue tumours. **Virchows Arch 1997; 431:83-94.**

41. Dei Tos AP, et al. Molecular aberrations of the G1-S cell cycle checkpoint in myxoid and round cell liposarcoma. **Am J Pathol 1997; 151:1531-1539.**

1998



42. Dal Cin P, Dei Tos AP, et al. Immature teratoma of the pineal gland with i(12p). **Acta Neuropathol** 1998; **95:107-110**.
43. Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM. Fibrosarcomatous ("high grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. **Am J Surg Pathol** 1998; **22:576-587**.
44. Dei Tos AP, et al. Calretinin: a novel tool for diagnostic immunohistochemistry. **Adv Anat Pathol** 1998; **5:61-66**.
45. Chilosi M, Dei Tos AP, et al. bcl.2 expression in synovial sarcoma. Author's reply. **J pathol** 184; **337-340**.
46. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, et al. Cyclin D3 expression in human normal tissue and neoplasms. **J Pathol** 1998; **185; 159-166**.
47. Dei Tos AP, et al. Primary liposarcoma of the skin: a rare neoplasms with unusual high grade features. **Am J Dermatopathol** 1998; **20:332-338**.
48. Dei Tos AP, et al. Synovial sarcoma of the larynx and hypopharynx: pathologic and diagnostic evaluation. **Ann Otol Rhinol Laryngol** 1998; **107:1080-1085**.
49. Dei Tos AP. News and confirmations in mesenchymal neoplasia. **Pathologica** 1998; **90: 54-56**.
50. Dal Cin P, Wanschura S, Kazmierczak B, Tallini G, Dei Tos AP, et al. Amplification and expression of the HMGIC gene in a benign endometrial polyp. **Genes Chromosomes Cancer** 1998; **22:95-99**.
51. Doglioni C, Dei Tos AP, Barbareschi M. Malt Lymphoma: an update. **Pathologica** 1998; **90:313-317**.
52. Foschini MP, Macchia S, Losi L, Dei Tos AP, et al. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis.. **Virchows Arch** 1998; **433: 267-273**.
53. Dei Tos AP, et al. The relevance of genetics and molecular pathology in mesenchymal tumours. **Adv Clin Pathol** 1998; **2:197-204**.
54. Giannini C, Dei Tos AP. La diagnosi neuropatologica e le sue implicazioni terapeutiche. **Pathologica** 1998; **90; 408-411**.
- 1999**
55. Losi L, Buonamici L, Dal Cin P, Giannini C, Dei Tos AP, et al. Citogenetica di tumori del sistema nervoso centrale: studio casistico e revisione della letteratura. **Pathologica** 1999; **91:249-255**.
56. Maestro R, Dei Tos AP, et al. Twist is a potential oncogene that inhibits apoptosis. **Genes Dev** 1999; **13:2207-2217**.
57. Midena E; de Belvis V; Dei Tos AP et al. Isolated brain metastasis of malignant choroidal melanoma 27 years after enucleation. **Arch Ophthalmol**, 1999; **117:11, 1553-1556**.
58. Mazzon D; Zanardo G; Dei Tos AP. Repeat percutaneous tracheostomy with the Ciaglia technique

after transalaryngeal tracheostomy. **Intensive Care Med**, 1999; 25: 639.

59. Dei Tos AP. Adipocytic tumors: new entities and evolving concepts. **Rev Esp Patol** 1999, 32:271-282.

60. Dei Tos AP, et al. Absence of S-100 protein immunoreactivity in cellular blue nevus: a potential diagnostic pitfall. **Applied immunohistochem** 1999; 7: 255-259.

## 2000

61. Oliveira A, Dei Tos AP, et al. Primary giant cell tumor of soft tissue. A clinicopathologic analysis of 21 cases. **Am J Surg Pathol**. 2000; 24:248-256.

62. Dei Tos AP et al. Coordinated expression and amplification of the MDM2, CDK4 and HMGI-C genes in atypical lipomatous tumors. **J Pathol** 2000, 180; 531-536.

63. Dei Tos AP. Liposarcoma: new entities and evolving concept. **Ann Pathol** 2000; 4:252-266.

64. Oliveira A, Dei Tos AP, Fletcher CDM, Nascimento A. Primary giant cell tumors of soft tissue. Author's reply. **Am J Surg Pathol** 2000; 24:1175-1176.

## 2001

65. Dei Tos AP. Lipomatous tumours. **Curr Diagn Pathol** 2001; 7:8-16. 1997-1998.

66. Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. p53 expression in pleomorphic xanthoastrocytoma. **Neurogenetics** 2001; 3: 159-162.

67. Zembowicz A, McCusker M, Chiarelli C, Dei Tos AP, et al. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. **Am J Dermatopathol** 2001; 23:167-75.

68. Orvieto E, Dei Tos AP. Determinazione di HER2 nel carcinoma mammario: quale approccio metodologico? **Pathologica** 2001; 93:183-188.

69. Laurino L, Furlanetto A, Orvieto E, Dei Tos AP. Well differentiated liposarcoma (atypical lipomatous tumors). **Sem Diagn Pathol** 2001; 18:258-262.

70. Orvieto E, Furlanetto A, Laurino L, Dei Tos AP. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. **Sem Diagn Pathol** 2001; 18: 267-273.

## 2002

71. Dedeurwaerdere F, Giannini C, Sciò R, Rubin BP, Perilongo G, Borghi L, Ballotta ML, Cornips E, Demunter A, Maes M, Dei Tos AP. Primary peripheral PNET/Ewing's sarcoma of the dura: a clinicopathologic entity distinct from central PNET. **Mod Pathol** 2002, 15: 673-678.

72. A. Furlanetto, Dei Tos AP. Squamous cell carcinoma arising in a ciliated hepatic foregut cyst. **Virchows Arch** 2002, 441:296-8.

73. Dei Tos AP. Atypical lipomatous tumor and dedifferentiated liposarcoma: are they still controversial

concepts? **Histopathology 2002, 41 (suppl): 227-230.**

### 2003

74. Dei Tos AP. The reappraisal of GIST: from Stout to the KIT revolution. **Virchows Arch 2003; 443-421-428.**

75. Dei Tos AP. Role of HER-2 in the treatment of breast carcinoma. **Pathologica. 2003; 95:278.**

76. Dei Tos AP. GIST: from diagnosis to molecular therapy. **Pathologica. 2003;95:251.**

### 2004

77. Rossi S., Orvieto E., Furlanetto A., Laurino L., Ninfo V, Dei Tos AP. The utility of the immunohistochemical detection of Fli-1 expression in round cell and vascular neoplasm using a monoclonal antibody. **Mod Pathol 2004; 17: 547-552.**

78. Hogendoorn PCW, Collin F, Daugaard S, Dei Tos AP, Fisher C, Schneider U, Sciot R. Changing concepts in the pathological basis of Soft Tissue and Bone sarcoma treatment. **Eur J Cancer 2004, 40:1644-54.**

79. Conconi MT, Rocco F, Spinazzi R, Tommasini M, Valfrè C, Busetto R, Polesel E, Albertin G, Dei Tos A, Iacopetti I, Cecchetto A, Zussa C, Grigioni M, Parnigotto PP, Nussdorfer GG. Biological fate of tissue-engineered porcine valvular conduits xenotransplanted in the sheep thoracic aorta. **Int J Mol Med. 2004, 14:1043-1048.**

80. Chilosi M, Dei Tos AP, Doglioni C. Ancillary methods, marketing, and health care models. To be precise: between ethics and marketing, an investigation of quality or of profit? **Pathologica 2004; 96:43-44.**

### 2005

81. Lazar AJ, Calonje E, Grayson W, Dei Tos AP, Mihm MC Jr, Redston M, McKee PH. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. **J Cutan Pathol. 2005; 32:148-157.**

82. Blay J-Y, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile J-F, Gronchi A, Hogendoorn AP, Joensuu H, Le Cesne A, Mac Clure J, Maurel J, Nupponen I, Ray-Coquard I, Reichart P, Sciot R, Stroobants S, van Glabbeke A, van Oosterom A, Demetri GD. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of the 20-21 March 2004, under the auspices of ESMO. **Ann Oncol 2005; 16:566-578.**

83. Dei Tos AP, Ninfo V. Biologia molecolare dei GIST. In M Lopez (ed) GIST: tumori stromali gastrointestinali. **Editrice Universo Roma, 2005, pp. 9-14.**

84. Chilosi M, Doglioni C, Dei Tos AP. New diagnostic markers: podoplanin-d2-40. **Pathologica. 2005; 97(3):158-9.**

85. Dei Tos AP, Ellis I. Assessing Epidermal Growth Factor Receptor expression in tumours: what is the value of current test methods? **Eur J Cancer 2005; 41:1383-1392.**

86. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M. Characterization of thyroid "follicular neoplasms" in fine needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. **Endocr Relat Cancer**

**2005 12:305-317.**

87. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP. Rabbit Monoclonal Antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonals. **Am J Clin Pathol** 2005; **124:295-302**.

88. Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, Weiss SW. Morphologic and Immunophenotypic Diversity in Ewing Family Tumors: A Study of 66 Genetically Confirmed Cases. **Am J Surg Pathol**, 2005; **29:1025-1033**.

**2006**

89. Longatti P, Basaldella L, Orvieto E, Dei Tos AP, Martinuzzi A. Aquaporin 1 expression in cystic hemangioblastomas. **Neurosci Lett**. 2006 **16;392:178-80**.

90. Mentzel T, Dei Tos AP, Sapi Z, Kutzner H. Myopericytoma of skin and soft tissues: clinicopathologic and immunohistochemical study of 55 cases. **Am J Surg Pathol**, 2006; **30:104-113**.

91. Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? **Histopathology** 2006; **48:51-62**.

92. Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Csemi G, Dei Tos AP, Fortunati N, Catalano MG, Bussolati G. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. **Mod Pathol**. 2006;**19:599-606**.

93. Rossi S, Ou W, Tang D, Bhattacharya D, Dei Tos AP, Fletcher JA, Loda. Fatty acid synthase is overexpressed in gastrointestinal stromal tumors (GIST). **J Pathol** 2006, **209:369-375**.

94. Tedoldi S, Paterson JC, Cordell J, Tan S-Y, Jones M, Manek S, Dei Tos AP, Masir N, Natkunam Y, Robertson H, Pileri SA, Facchetti F, Hansmann M.L, Mason DY, Marafioti T. Jaw1/LRMP: a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. **J Pathol** 2006, **209:454-463**.

95. Longatti P, Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A. Aquaporin(s) expression in choroid plexus tumours. **Pediatr Neurosurg**. 2006;**42:228-33**.

96. Gottardi M, Gattei V, Degan M, Bomben R, Zucchetto A, Tecchio C, Laurino L, Zanatta L, Dei Tos AP, Mordacchini M, Canal F, Gherlinzoni F. Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. **Leuk Lymphoma**. 2006 May;**47:885-889**.

**2007**

97. Basaldella L, Orvieto E, Dei Tos AP, Dalla Barbera M, Valente ML, Longatti PL. Causes of arachnoid cyst development and expansion. **Neurosurg Focus** 2007; **22:1-7**.

98. Rossi S, Nascimento AG, Canal F, Dei Tos AP. Small round cell neoplasms of soft tissue: an integrated diagnostic approach. **Curr Diagn Pathol** 2007; **13:150-163**.

99. Leonardo E, Volante M, Barbareschi M, Cavazza A, Dei Tos AP, Bussolati G, Papotti M. Cell membrane reactivity of Mib-1 antibody to Ki67 in human tumors: fact or artifact? **Appl Imm Mol Morph**; 2007, **15:220-223**.

100. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. **Int J Biol Markers**, 2007: Jan-Mar;22 Suppl 4:S3-9.

101. Sapino A, Montemurro F, Marchiò C, Viale G, Kulka J, Donadio M, Bottini A, Botti G, Dei Tos AP, Bersiga A, Di Palma S, Truini M, Sanna G, Aglietta M, Bussolati G. Patients With Advanced Stage Breast Carcinoma Immunoreactive to Biotinylated Herceptin Are Most Likely to Benefit From Trastuzumab-based Therapy: An Hypothesis-generating Study. **Ann Oncol**. 2007;18(12):1963-8.

102. Corradi D, Maestri R, Palmisano A, Bosio S, Greco P, Manenti I, ferretti S, Cobelli R, Moroni G, Dei Tos AP, Buzio C, Vaglio A. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis with other fibrosing disease. **Kidney International**, 2007;72:742-53.

103. Basaldella L, Orvieto E, Dei Tos AP, Della Barbera M, Valente M, Longatti P. Causes of arachnoid cyst development and expansion. **Neurosurg Focus**. 2007; 15; 22:E4.

104. Rossi S, Dei Tos AP. Advances in gastrointestinal stromal tumor therapy. **Adv Anat Pathol**. 2007;14:302.

105. Rossi S, Dei Tos AP. Chromosomal imbalances and cytogenetic progression in gastrointestinal stromal tumor. **Adv Anat Pathol**. 2007;14:301-302.

106. Rossi S, Szuhai K, Ijszenga M, Tanke HJ, Zanatta L, Sciot R., Fletcher CDM, Dei Tos AP, Hogendoorn PCW. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. **Clin Cancer Res** 2007, 2007 15;13(24):7322-8.

## 2008

107. Stefani PM, Laurino L, Zanatta L, Valori L, Dei Tos AP, Gherlinzoni F. Primary cardiac onset of disseminated Burkitt's lymphoma. **Ann Hematol**. 2008;87(6):487-488.

108. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 Suppl 2:89-93.

109. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Group Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 Suppl 2:35-8.

110. Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, Hornick JL, Grizzo A, Sartor C, Mandolesi A, Sciot R, Debiec-Rychter M, Dei Tos AP, Maestro R. Multiple primary sporadic GIST in the adult: an underestimated entity. **Clin Cancer Res** 2008; 15; 5715-21.

111. Marton E, Feletti A, Basaldella L, Dei Tos AP, Bendini M, Longatti P. Atypical cystic meningioma overexpressing AQP1 in early infancy: case report with literature review. **Acta Paediatr**. 2008;97:1145-1149.

112. Licci S, Canal F, Dei Tos AP, Fedrigo M, Gherlinzoni F, Brenna A, Zanatta L, Rossi S. Aleukemic granulocytic sarcoma with associated T-cell lymphoblastic lymphoma in the same lymph node: morphologic features and molecular signatures. **Leuk Lymphoma** 2008; 49:1411-1415.

113. Gottardi M, Danesin C, Canal F, Dei Tos AP, Maria Stefani P, Calistri E, Salvadori U, Gherlinzoni

F. Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. **Leuk Lymphoma. 2008; 25:1-3.**

114. Rossi S, Laurino L, Dei Tos AP. Desmoid-type fibromatosis: from morphology to molecular genetics: **Diagnostic Histopathology 2008; 14:546-551.**

115. Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, Dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Claravezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M. Retrospective evaluation of clinical outcomes in patients with HER2-positive breast cancer progressing on Trastuzumab-based therapy in the pre-Lapatinib era. **Clinical Breast cancer 2008; 8:436-442.**

## 2009

116. Stacher E, Gruber-Mösenbacher U, Halbwedl I, Dei Tos AP, Cavazza A, Papotti M, Carvalho L, Huber M, Leander Ermer L, Popper HH. The VEGF-System in Primary Pulmonary Angiosarcomas and Haemangiopericytomas: New Potential Therapeutic Targets? **Lung Cancer. 2009, 65:49-55.**

117. Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP. Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. **Hum Pathol. 2009;40:1040-4.**

118. Rossi S, Rodriguez FJ, Mota RA, Dei Tos AP, Di Paola FD, Bendini M, Agostini S, Longatti P, Jenkins RB, Giannini C. Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. **Acta Neuropathol. 2009 Jun 27.**

119. Dei Tos AP, Wagner AJ, Modena P, Comandone A, Leyvraz S. Epithelioid soft tissue tumors. **Semin Oncol. 2009; 36:347-357.**

120. Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS. Small round cell sarcomas. **Semin Oncol. 2009;36:338-346.**

121. Rossi S, Rodriguez F, Dei Tos AP, Di Paola F, Bendini M, Jenkins R, Giannini C. Diffuse leptomeningeal glioneuronal tumors: a new entity? **Brain Pathol. 2009;19(4):745.**

122. Romeo S, Hogendoorn PC, Dei Tos AP. Benign cartilaginous tumors of bone: from morphology to somatic and germ-line genetics. **Adv Anat Pathol. 2009 ;16:307-15.**

## 2010

123. Massi, D, Franchi A, Alos L, Cook M, Di Palma S, Enguita AB, Ferrara G, Kazakov DV, Mentzel T, Michal M, Panelos J, Rodriguez-Peralto J-L, Santucci M, Tragni G, Zioga A, Dei Tos AP. Primary Cutaneous Leiomyosarcoma: Clinico-pathologic analysis of 36 cases **Histopathology 2010;56:251-62.**

124. Dei Tos AP. The marriage between pathology and genetics: are we ready for clinical use?. **Ann Surg Oncol. 2010;17:668-9.**

125. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. **Virchows Arch. 2010;456:219-34.**

126. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C,

Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. PML down-regulation in soft tissue sarcomas. **J Cell Physiol.** 2010; 29; 224: 644-648.

127. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiu AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2010; 21 Suppl 5:v204-13.

128. Basaldella L, Perin A, Orvieto E, Marton E, Itskevich D, Dei Tos AP, Longatti P. A preliminary study of aquaporin 1 immunolocalization in chronic subdural hematoma membranes. **J Clin Neurosci.** 2010;17:905-907.

129. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2010; 21 Suppl 5:v98-102.

130. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2010; 21 Suppl 5:v198-203.

131. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A, Dei Tos AP. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. **Histopathology.** 2010; 57:259-270.

132. Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. The burden of rare cancers in Europe. **Adv Exp Med Biol.** 2010;686:285-303.

133. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, Casali PG, Talamini R, Maestro R, Dei Tos AP. Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size. **Am J Surg Pathol.** 2010; 34:1480-91.

134. Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero F, Mello-Grand M, Dei Tos AP, Elena Giulotto, Giulia Taraboletti, Maurizio D'Incalci, Chiara Mondello. Reduced Expression of the ROCK inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. **PLOSone** 2010; 30;5: e14154.

## 2011

135. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, Castellucci P, Paterini P, Dei Tos AP, Stella F, Maleddu A, Pantaleo MA. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (Case reports). **Oncol Rep.** 2011;25:113-20.

136. Casali PG, Dei Tos AP. A new journal... on spindle cells. **Clin Sarcoma Res.** 2011 Jul 25;1(1):1.

137. Mertens F, Romeo S, Bovée JV, Tirabosco R, Athanasou N, Alberghini M, Hogendoorn PC, Dei Tos AP, Sciot R, Domanski HA, Aström K, Mandahl N, Debiec-Rychter M. Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features. **Clin Sarcoma Res.** 2011 Oct 13;1(1):10.

138. Hostein I, Debiec-Rychter M, Olschwang S, Bringuier PP, Toffolatti L, Gonzalez D, Forget S, Escande F, Morzuch L, Tamborini E, Faur N, Pilotti S, Dei Tos P, Emile JF, Coindre JM. A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours. **J**

**Gastroenterol. 2011 May; 46 (5):586-94.**

139. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG. Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. **Gynecol Oncol. 2011;123:553-6.**

140. Dei Tos AP. Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers. **J Pathol. 2011; 223:565-6.**

141. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; The RARECARE working group. Rare cancers are not so rare: The rare cancer burden in Europe. **Eur J Cancer. 2011; 47:2493-511.**

142. Dei Tos AP, Laurino L, Bearzi I, Messerini L, Farinati F; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Gastrointestinal stromal tumors: the histology report.. **Dig Liver Dis. 2011 Mar;43 Suppl 4:S304-9.**

143. Romeo S, Dei Tos AP. Clinical application of molecular pathology in sarcomas. **Curr Opin Oncol. 2011; 23:379-84.**

144. Marton E, Rossi S, Feletti A, Dei Tos AP, Longatti P. Intramedullary malignant peripheral nerve sheath tumor. **J Neurooncol. 2011 Nov; 105 (2):441-3.**

145. Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M, Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. **Histopathology. 2011; 59:1071-1080.**

146. Richter KK, Dempster A, Dei Tos AP, Premkumar R, Jackson C. Challenging differential diagnosis of a wild-type gastrointestinal stromal tumour (GIST) or rare reticular perineurioma of the stomach? The role for mutational analysis. **N Z Med J. 2011;124(1331):45-55.**

147. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP. Natural History of Imatinib-naive GISTs: A Retrospective Analysis of 929 Cases With Long-term Follow-up and Development of a Survival Nomogram Based on Mitotic Index and Size as Continuous Variables. **Am J Surg Pathol. 2011; 35:1646-1656.**

## 2012

148. Corradi D, Alquati S, Bertoni F, Bartoli V, Dei Tos AP, Wenger D, Giannini C. A Small Intraneural Epithelioid Malignant Peripheral Nerve Sheath Tumour of the Median Nerve Simulating a Benign Lesion. Description of a Case and Review of the Literature. **Pathol Oncol Res. 2012 Jan;18(1):101-6.**

149. Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, Maleddu A, Mandrioli A, Lolli C, Saponara M, Di Scioscio V, Zompatori M, Catena F, Fusaroli P, Dei Tos AP, Pantaleo MA. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. **Med Oncol. 2012 Mar 29 (1): 144-50.**

150. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. **Ann Oncol. 2012 Feb; 23 (2):501-8 .**



151. Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. **J Cell Physiol.** 2012 Apr; **227(4):1657-62.**

152. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi B, Bordoni A, Magnusson MK, Linke Z, Jozef Sufliarsky, Massimo F, Jonasson GJ, Dei Tos AP, Rutkowski P. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis of pooled population-based cohorts. **Lancet Oncol.** 2012 Mar;**13(3):265-74.**

153. D'Amico FE, Ruffolo C, Romeo S, Massani M, Dei Tos AP, Bassi N. Clear Cell Sarcoma of the Ileum: Report of a Case and Review of the Literature. **Int J Surg Pathol.** 2012 Aug;**20 (4):401-6.**

154. Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. **Am J Hematol.** 2012 ; **87:22-25.**

155. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. **J Clin Oncol.** 2012; **10;30:850-6.**

156. Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. **Eur J Cancer.** 2012; **48:159-69.**

157. Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. **Eur J Cancer.** 2012 ;**48:159-69.**

158. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN; RARECARE working group. Incidence and survival of rare urogenital cancers in Europe. **Eur J Cancer** 2012;**48:456-64.**

159. Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Stojan P, Licitra L; RARECARE Working Group. Rare cancers of the head and neck area in Europe. **Eur J Cancer.** 2012;**48:783-96.**

160. Siesling S, van der Zwan JM, Izarzugaza I, Jaal J, Treasure T, Foschi R, Ricardi U, Groen H, Tavilla A, Ardanaz E; RARECARE Working Group. Rare thoracic cancers, including peritoneum mesothelioma. **Eur J Cancer** 2012;**48:949-60.**

161. Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, Navarro C, Virgili G; RARECARE WG. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. **Eur J Cancer.** 2012;**48:1167-75.**

162. Romeo S. Dei Tos AP. Hogendoorn PCW. The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours. **Diagnostic Histopathology** 2012, **18 (2):81-85.**

163. Ray-Coquard I, Montesco MC, Coindre JM, Dei Tos AP, Lurkin A, Ranchère-Vince D, Vecchiato A, Decouvelaere AV, Mathoulin-Pélissier S, Albert S, Cousin P, Cellier D, Toffolatti L, Rossi CR, Blay JY; for the Conticanet group. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. **Ann Oncol.** 2012 Sep; **23 (9):2242-9.**

164. Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandona P, Ducimetiere F, Blay JY, Gilly FN, Siani

C, Biron P, Ranchere-Vince D, Decouvlaere AV, Thiesse P, Bergeron C, Dei Tos AP, Coindre JM, Rossi CR, Ray-Coquard I. Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. **BMC Health Serv Res.** 2012; **28**:12:82.

165. Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, Buja A, Fedeli U, Cegolon L, Frasson A, Ranchère-Vince D, Montesco C, Ray-Coquard I, Rossi CR. Incidence of soft tissue sarcoma and beyond: A population-based prospective study in 3 European regions. **Cancer.** 2012 Nov 1; **118** (21):5339-48.

166. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. **Lancet.** 2012 **19**;379:1879-86.

167. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Lombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, A P Dei Tos, Casali PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. **Cancer.** 2012 Dec 1; **118**(23):5857-66.

168. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). **Ann Oncol.** 2012 Dec; **23** (12):3171-9.

169. Romeo S, Bovée JV, Kroon HM, Tirabosco R, Natali C, Zanatta L, Sciot R, Mertens F, Athanasou N, Alberghini M, Szuhai K, Hogendoorn PC, Dei Tos AP. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. **Virchows Arch.** 2012 Nov; **461** (5):561-70.

170. Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, Rosano C, Dei Tos AP, Doglioni C, Maestro R. A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation. **Cancer Cell.** 2012 **11**;22:404-15.

171. Nannini M, Pantaleo MA, Catena F, Romano S, Tondo S, Pirini MG, Lolli C, Maleddu A, Mandrioli A, Gatto L, Saponara M, Pallotti MC, Dei Tos AP, Pinna AD, Biasco G. Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. **Int J Surg Case Rep.** 2012 Sep **19**;4(1):7-10.

172. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, López-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. **Clin Sarcoma Res.** 2012 Dec **29**;2(1):25.

173. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. **Eur J Cancer.** 2012 Nov; **48** (17):3257-66.

174. Tamborini E, Rossi S, Tarantino E, Mauro V, Dei Tos AP, Pilotti S. Platelet-derived growth factor receptor alpha expression improves the diagnostic assessment of gastrointestinal stromal tumours. **Histopathology.** 2012; **61**:1240-5.

175. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO

Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9.**

176. ESMO / European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55.**

177. ESMO / European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol. 2012 Oct;23 Suppl 7:vii100-9.**

### 2013

178. Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. **Expert Opin Investig Drugs. 2013 Jan; 22(1):1-7.**

179. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. **Ann Oncol. 2013 Mar; 24 (3): 817-23.**

180. Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L; Liguria GIST Unit, Bianchi Scarrà G. Molecular characterization of an Italian series of sporadic GISTs. **Gastric Cancer. 2013 Oct; 16 (4):596-601.**

181. Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S, Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. **Clin Sarcoma Res. 2013 Apr 3;3:4.**

182. van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T; the RARECARE WG. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. **Eur J Cancer. 2013 Jul;49(11):2565-78.**

183. Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos PA, Fletcher CD. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. **Am J Surg Pathol. 2013 Mar;37(3):385-92**

184. Brenca M, Rossi S, Lorenzetto E, Piccinin E, Piccinin S, Rossi FM, Giuliano A, Dei Tos AP, Maestro R, Modena P. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. **Mol Cancer Ther. 2013 Jun;12(6):1060-72.**

185. Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: A retrospective study. **Eur J Cancer. 2013 Jul;49(10):2376-83.**

186. Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. **Clin Sarcoma Res. 2013 Apr 17;3(1):6.**

187. Tomek M, Bravi I, Mendoza N, Alsafi A, Mehta A, Molinaro L, Singh P, Radotra B, Dei Tos AP,

Roncaroli F. Spinal extradural solitary fibrous tumor with retiform and papillary features. **Ann Diagn Pathol.** 2013 Jun;17(3):281-7.

188. Sanfilippo R, Dei Tos AP, Casali PG. Myxoid liposarcoma and the mammalian target of rapamycin pathway. **Curr Opin Oncol.** 2013 Jul;25(4):379-83.

189. Neuville A, Ranchère-Vince D, Dei Tos AP, Montesco MC, Hostein I, Toffolatti L, Chibon F, Pissaloux D, Alberti L, Decouvelaere AV, Albert S, Rossi CR, Blay JY, Coindre JM. Impact of Molecular Analysis on the Final Sarcoma Diagnosis: A Study on 763 Cases Collected During a European Epidemiological Study. **Am J Surg Pathol.** 2013 Aug;37(8):1259-68.

190. Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino Ciaramella P, Ventura L, Gambacorta M, Dei Tos AP, Loli P, Mannelli M, Mantero F, Berruti A, Terzolo M, Papotti M. The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. **Am J Surg Pathol.** 2013 Sep;37(9):1433-40

191. Dal Maso L; AIRTUM Working Group. Lung cancer incidence in young women (20-49 years) reached incidence in young men. **Epidemiol Prev.** 2013 Mar-Jun;37(2-3):187.

192. Ricci R, Dei Tos AP, Rindi G. GISTogram: a graphic presentation of the growing GIST complexity. **Virchows Arch.** 2013 Oct;463(4):481-7.

193. Di Giorgio E, Clocchiatti A, Piccinin S, Sgorbissa A, Viviani G, Peruzzo P, Romeo S, Rossi S, Dei Tos AP, Maestro R, Brancolini C. MEF2 Is a Converging Hub for Histone Deacetylase 4 and Phosphatidylinositol 3-Kinase/Akt-Induced Transformation. **Mol Cell Biol.** 2013; 33:4473-91.

194. Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. **Clin Sarcoma Res.** 2013 Dec 18;3(1):16.

195. Ricci R, Dei Tos AP, Rindi G. On the prevalence of KRAS mutations in GISTs. **Virchows Arch.** 2013 Dec;463(6):847.

196. Dei Tos AP. A current perspective on the role for molecular studies in soft tissue tumor pathology. **Semin Diagn Pathol.** 2013; 30:375-81.

197. Stacchiotti S, Marrari A, Dei Tos AP, Casali PG. Targeted Therapies in Rare Sarcomas: IMT, ASPS, SFT, PEComa, and CCS. **Hematol Oncol Clin North Am.** 2013 Oct;27(5):1049-61.

198. Crocetti E, Rondelli R, Dal Maso L; AIRTUM Working Group. About 1,400 new cancer diagnosis in Italian children (0-14 years) are attended every year (7,000 in 5 years). **Epidemiol Prev.** 2013 Nov-Dec;37(6):410.

199. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours. **Epidemiol Prev.** 2013 Jul-Oct;37(4-5 Suppl 1):1-152.

200. Pisani P, Buzzoni C, Dal Maso L; AIRTUM Working Group. Cancer incidence in 0-14-year children shows little geographical differences. **Epidemiol Prev.** 2013 Jul-Oct;37(4-5):342.

## 2014

201. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P,

Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. **Mol Cancer Ther.** 2014 Jan;**13(1):249-59**.

202. Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. **Histopathology.** 2014 Jan;**64(1):38-52**.

203. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. **Ann Oncol.** 2014 Mar;**25(3):578-83**.

204. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, Casali PG. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. **Eur J Cancer.** 2014 Mar;**50(4):784-92**.

205. Cacciatore M, Dei Tos AP. Challenging epithelioid mesenchymal neoplasms: mimics and traps. **Pathology** 2014;**46(2):126-34**

206. Vogel D, Righi A, Kreshak J, Dei Tos AP, Merlino B, Brunocilla E, Vanel D. Lipofibromatosis: magnetic resonance imaging features and pathological correlation in three cases. **Skeletal Radiol.** 2014 May;**43(5):633-9**.

207. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. **Ann Oncol.** 2014 Mar;**25(3):578-83**.

208. Stiller CA, Trama A, Brewster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; RARECARE Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. **Cancer Epidemiol.** 2014 Dec;**38(6):670-8**.

209. Feletti A, Marton E, Bendini M, Zanatta L, Valori L, Dei Tos AP, Di Paola F, Longatti P, Rossi S. Anaplastic ependymoma of the third ventricle. **Brain Tumor Pathol.** 2014 Oct;**31(4):274-81**.

210. Sambataro M, Segnanfredo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP. Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot. **Int J Vasc Med.** 2014; **2014:589412**.

211. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marraud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, Dei Tos AP, van der Graaf WT; for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. **Lancet Oncol.** 2014;**15:415-23**.

212. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG.

Activity of sunitinib in extraskeletal myxoid chondrosarcoma. **Eur J Cancer.** 2014 Jun;**50(9):1657-64.**

213. Oudijk L, de Krijger RR, Rapa I, Beuschlein F, de Cubas AA, Dei Tos AP, Dinjens WN, Korpershoek E, Mancikova V, Mannelli M, Papotti M, Vatrano S, Robledo M, Volante M. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. **J Clin Endocrinol Metab.** 2014 Jul;**99(7):E1376-80.**

214. Fusco M, Trama A, Buzzoni C; AIRTUM Working Group. In the last 15 years, survival in Italian children (0-14 years) is increased to 12%. **Epidemiol Prev.** 2014 Jan-Feb;**38(1):62.**

215. Dal Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, Caldarella A, Dei Tos AP, Falcini F, Autelitano M, Masanotti G, Ferretti S, Tisano F, Tirelli U, Crocetti E, De Angelis R; the AIRTUM Working group. Long-term survival, prevalence, and cure of cancer: A population-based estimation for 818,902 Italian patients and 26 cancer types. **Ann Oncol.** 2014 Nov;**25(11):2251-60.**

216. Crocetti E, Madeddu A, Mangone L; AIRTUM Working Group; AIRTUM Working Group [In 2014 cancer registration covers more than half of the Italian population]. **Epidemiol Prev.** 2014 May-Aug;**38(3-4):273.**

217. Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP. MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. **Virchows Arch.** 2014 Nov;**465(5):579-86.**

218. Buzzoni C, Ferretti S, Dal Maso L; AIRTUM Working Group. After the increasing trend in the Nineties, in Italy incidence of tumours in children (0-14 years) is decreasing. **Epidemiol Prev.** 2014 Mar-Apr;**38(2):146.**

219. Comba P, Ricci P, Iavarone I, Pirastu R, Buzzoni C, Fusco M, Ferretti S, Fazzo L, Pasetto R, Zona A, Crocetti E; ISS-AIRTUM Working Group for the study of cancer incidence in contaminated sites. Cancer incidence in Italian contaminated sites. **Ann Ist Super Sanita.** 2014;**50(2):186-91.**

220. Dal Maso L, Guzzinati S, De Angelis R; AIRTUM Working Group. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy. **Epidemiol Prev.** 2014;**38(6 Suppl 1):1-122.**

221. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. **Clin Sarcoma Res.** 2014 Nov **22;4(1):16**

222. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. **Eur J Cancer.** 2014 Nov;**50(17):3021-8.**

223. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2014 Sep;**25 Suppl 3:iii21-6.**

224. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2014 Sep;**25 Suppl 3:iii113-23. doi:**

225. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2014 Sep;**25 Suppl 3:iii102-12**

226. Tucci M, Stucci S, Vallarelli S, Gesualdo L, Brunetti O, Dei Tos AP, Silvestris F. Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. *J Clin Oncol*. 2015 May 10;33(14):e66-70.

2015

227. **Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, Dei Tos AP**. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. *Gut*. 2015 May;64(5):784-90.

228. **Righi A, Gambarotti M, Picci P, Dei Tos AP, Vanel D**. Primary pseudomyogenic haemangioendothelioma of bone: report of two cases. *Skeletal Radiol*. 2015 May;44(5):727-31.

229. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S. Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. *Am J Surg Pathol*. 2015 Mar;39(3):383-93.

230. Buzzoni C, Crocetti E, De Angelis R, Dal Maso L; AIRTUM Working Group. Cancer survival in Italy in 2000-2007 is better than in Europe. *Epidemiol Prev*. 2015 Jul-Aug;39(4):270

231. Lartigue L, Neuville A, Lagarde P, Brulard C, Rutkowski P, Dei Tos P, Wardelmann E, Debiec-Rychter M, Italiano A, Coindre JM, Chibon F. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy. *Eur J Cancer*. 2015 Jan;51(1):75-83.

232. Righi A, Gambarotti M, Longo S, Benini S, Gamberi G, Cocchi S, Vanel D, Picci P, Bertoni F, Simoni A, Franchi A, Dei Tos A. Small Cell Osteosarcoma: Clinicopathologic, Immunohistochemical, and Molecular Analysis of 36 Cases. *Am J Surg Pathol*. 2015 May;39(5):691-9.

233. Blay JY, Casali PG, Dei Tos AP, Le Cesne A, Reichardt P. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. *Oncology*. 2015;89(1):1-13.

234. Romeo S, Rossi S, Acosta Marín M, Canal F, Sbaraglia M, Laurino L, Mazzoleni G, Montesco MC, Valori L, Campo Dell'Orto M, Gianatti A, Lazar AJ, Dei Tos AP. Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases. *Clin Sarcoma Res*. 2015 Feb 12;5:7.

235. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. *Anticancer Drugs*. 2015 Jul;26(6):678-81.

236. Zanatta L, Valori L, Cappelletto E, Pozzebon ME, Pavan E, Dei Tos AP, Merkle D. Reagent and Labor Cost Optimization through Automation of Fluorescence In Situ Hybridization (FISH) with the VP 2000: An Italian Case Study. *J Lab Autom*. 2015 Feb;20(1):25-31.

237. Vincenzi B, D'Onofrio L, Frezza AM, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G. Classic Kaposi Sarcoma: to treat or not to treat? *BMC Res Notes*. 2015; 10;8(1):138.

238. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C,

Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. Deregulation of dicer and mir-155 expression in liposarcoma. **Oncotarget**. 2015 Apr 30;6(12):10586-91.

239. Crocetti E, Buzzoni C, Dal Maso L; AIRTUM Working Group. Italy 2014: 1,000 new cancer cases every day, but mortality is decreasing. **Epidemiol Prev**. 2015 Jan-Feb;39(1):62.

240. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP. KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST: A Population-based Study. **Am J Surg Pathol**. 2015 Jul;39(7):922-30.

241. Sandrucci S, Gatta G, Trama A, Dei Tos AP, Casali PG. Specialized teams or specialist networks for rare cancers? **Eur J Surg Oncol**. 2015 Sep;41(9):1115-7.

242. Scarpa M, Ruffolo C, Canal F, Scarpa M, Basato S, Erroi F, Fiorot A, Dall'Agnese L, Pozza A, Porzionato A, Castagliuolo I, Dei Tos AP, Bassi N, Castoro C. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. **Oncotarget**. 2015 Dec 22;6(41):43472-82.

243. Crocetti E, Buzzoni C, Dal Maso L; AIRTUM Working Group. The risk of cancer is slightly higher among Italian cancer patients than in the general population. **Epidemiol Prev**. 2015 Mar-Apr;39(2):140.

244. Paganini I, Sestini R, Cacciatori M, Capone GL, Candita L, Paoello C, Sbaraglia M, Dei Tos AP, Rossi S, Papi L. Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis. **Hum Pathol**. 2015 Aug;46(8):1226-31.

245. Righi A, Gambarotti M, Sbaraglia M, Frisoni T, Donati D, Vanel D, Dei Tos AP. Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis. **Clin Sarcoma Res**. 2015 Jun 6;5:15.

246. Di Liso E, Pennelli N, Lodovichetti G, Ghiotto C, Dei Tos AP, Conte P, Bonanno L. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. **Cancer Biol Ther** 2015;16(8):1128-35.

247. Righi A, Gambarotti M, Manfrini M, Benini S, Gamberi G, Cocchi S, Casadei R, Picci P, Vanel D, Dei Tos AP. Sclerosing epithelioid fibrosarcoma of the thigh: report of two cases with synchronous bone metastases. **Virchows Arch**. 2015 Sep;467(3):339-44.

248. Righi A, Paioli A, Dei Tos AP, Gambarotti M, Palmerini E, Cesari M, Marchesi E, Donati DM, Picci P, Ferrari S. High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma? **Clin Sarcoma Res**. 2015 Oct 29;5:23.

249. Fedeli U, Zorzi M, Urso ED, Gennaro N, Dei Tos AP, Saugo M. Impact of fecal immunochemical test-based screening programs on proximal and distal colorectal cancer surgery rates: A natural multiple-baseline experiment. **Cancer**. 2015 Nov 15;121(22):3982-9.

250. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcborg JR, Litière S, Blay JY. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish



Group for Research on Sarcomas. **J Clin Oncol.** 2015 Dec 20;**33(36):4276-83.**

251. Torrisi A, Castaing M, Giacomini A, Luminari S, Mangone L; AIRTUM Working Group. [AIRTUM and SIE for a shared definition of haemolymphopoietic cancers]. **Epidemiol Prev.** 2015 Mar-Apr;**39(2):208.**

## 2016

252. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. **Oncotarget.** 2016 Oct 25;**7(43):69412-69419.**

253. Gasparotto D, Rossi S, Campagna D, Scavina P, Tiziano FD, Marzotto A, Toffolatti L, Vitelli CE, Amini M, Dei Tos AP, Maestro R. Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor. **J Clin Oncol.** 2016 Apr 10;**34(11):e99-e103.**

254. Lupato V, Romeo S, Franchi A, Mantovani M, Dei Tos AP, Tirelli G, Da Mosto MC, Boscolo-Rizzo P. Head and Neck Extranodal Interdigitating Dendritic Cell Sarcoma: Case Report and Review of the Literature. **Head Neck Pathol.** 2016 Jun;**10(2):145-51.**

255. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). **Clin Cancer Res.** 2016 Feb 15;**22(4):837-46.**

256. Gambarotti M, Righi A, Picci P, Bertoni F, Manfrini M, Donati D, Dei Tos AP, Vanel D. Pediatric chondrosarcomas: a retrospective review of 17 cases. **Histopathology.** 2016 Jun;**68(7):1073-8.**

257. Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, Valori L, Lamon S, Dei Tos AP, Maestro R. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. **J Pathol.** 2016 Mar;**238(4):543-9.**

258. Rossi S, Sbaraglia M, Dell'Orto MC, Gasparotto D, Cacciatore M, Boscato E, Carraro V, Toffolatti L, Gallina G, Niero M, Pilozi E, Mandolesi A, Sessa F, Sonzogni A, Mancini C, Mazzoleni G, Romeo S, Maestro R, Dei Tos AP. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. **Oncotarget.** 2016 May 24;**7(21):30109-18.**

259. Gambarotti M, Benini S, Gamberi G, Cocchi S, Palmerini E, Sbaraglia M, Donati D, Picci P, Vanel D, Ferrari S, Righi A, Dei Tos AP. CIC-DUX4 Fusion-Positive Round Cell Sarcomas of soft tissue and bone: a single institution morphologic and molecular analysis of 7 cases. **Histopathology.** 2016 Oct;**69(4):624-34.**

260. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Pechoux CL, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG, Gronchi A. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. **Lancet Oncol.** 2016 May;**17(5):671-80**

261. Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomini A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L; AIRTUM Working Group. Italian cancer figures - Report 2015: The burden of rare cancers in Italy. **Epidemiol Prev.** 2016 Jan-Feb;**40(1 Suppl 2):1-120.**

262. Dal Maso L, Buzzoni C, Guzzinati S, Crocetti E; AIRTUM Working Group . Italy 2015: 3 million Italians are living after a cancer diagnosis, both incidence and mortality are decreasing]. **Epidemiol Prev. 2016 Jan-Feb;40(1):75.**

263. Ray-Coquard I, Rizzo E, Blay JY, Casali P, Judson I, Hansen AK, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Litière S, Rutkowski P, Hohenberger P, Gronchi A, van der Graaf WT. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. **Gynecol Oncol. 2016; 142:95-101.**

264. Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. **Clin Sarcoma Res. 2016 Sep 14;6(1):15.**

265. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada PG, Sangalli C, Dei Tos AP, Marrari A, Casali PG, Stacchiotti S. Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review. **Clin Sarcoma Res. 2016; Sep 1;6(1):16.**

266. Righi A, Gambarotti M, Sbaraglia M, Sisto A, Ferrari S, Dei Tos AP, Picci P. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. **Hum Pathol. 2016; 58:15-23.**

267. Quero G, Musarra T, Carrato A, Fici M, Martini M, Dei Tos AP, Alfieri S, Ricci R. Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature. **Medicine (Baltimore). 2016 Jul;95(28):e4207.**

268. Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. **Ann Oncol. 2016; 27: 2283-2288**

269. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. **Ann Surg Oncol. 2016; 23:2735-44.**

270. Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. **Mol Cancer Res. 2016;14:820-9**

## 2017

271. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. **Eur J Cancer. 2017 Mar 8;76:84-92.**

272. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, Pilotti S, Gronchi A, Dei Tos AP, Maestro R. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. **Clin Cancer Res.** 2017; **23:273-282.**

273. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davi MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative., Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Whole-genome landscape of pancreatic neuroendocrine tumours. **Nature.** 2017; **543:65-71**

274. Gambarotti M, Righi A, Vanel D, Cocchi S, Benini S, Elli FM, Mantovani G, Ruggieri P, Boriani S, Donati D, Sbaraglia M, Dei Tos AP, Picci P. Fibrocartilaginous mesenchymoma of bone: a single-institution experience with molecular investigations and a review of the literature. **Histopathology.** 2017 Jul;**71(1):134-142.**

275. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. **Eur J Cancer** 2017; **8 :84-92.**

276. Ruffolo C, Toffolatti L, Canal F, Kotsafti A, Pagura G, Pozza A, Campo Dell'Orto M, Ferrara F, Massani M, Dei Tos AP, Castoro C, Bassi N, Scarpa M. Colorectal polypoid lesions and expression of vascular endothelial growth factor in a consecutive series of endoscopic and surgical patients. **Tumour Biol.** 2017 Mar;**39(3)**

277. Di Giorgio E, Franforte E, Cefalù S, Rossi S, Dei Tos AP, Brenca M, Polano M, Maestro R, Paluvai H, Picco R, Brancolini C. The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness. **PLoS Genet.** 2017 Apr **18;13(4):e1006752.**

278. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. **Lancet Haematol.** 2017 May;**4(5):e202-e217.**

279. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, Giovanni Casali P, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. **Genes Chromosomes Cancer** 2017 Jul;**56(7):582-586.**

280. D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatìs D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. **Eur J Cancer.** 2017;**78:122-132.**

281. Gambarotti M, Righi A, Frisoni T, Donati D, Vanel D, Sbaraglia M, Dei Tos AP. Dedifferentiated chondrosarcoma with "adamantinoma-like" features: A case report and review of literature. **Pathol Res Pract.** 2017 May.

282. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. **Lancet Oncol.** 2017 Jun;**18(6):812-822**.

283. Mancini I, Righi A, Gambarotti M, Picci P, Dei Tos AP, Billings SD, Simi L, Franchi A. Phenotypic and molecular differences between giant cell tumor of soft tissue and its bone counterpart. **Histopathology.** 2017 Sep;**71(3):453-460**.

284. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. **Oncotarget** 2017 May 17;**8(36):60036-60045**.

285. Bianchi G, Sambri A, Righi A, Dei Tos AP, Picci P, Donati D. Histology and grading are important prognostic factors in synovial sarcoma. **Eur J Surg Oncol.** 2017 Sep;**43(9):1733-1739**.

286. Furlan C, Polesel J, Barzan L, Franchin G, Sulfaro S, Romeo S, Colizzi F, Rizzo A, Baggio V, Giacomarra V, Dei Tos AP, Boscolo-Rizzo P, Vaccher E, Dolcetti R, Sigalotti L, Fratta E. Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. **Clin Epigenetics.** 2017 May 30;**9:58**

287. D'Amico FE, Ruffolo C, Romano M, Di Domenico M, Sbaraglia M, Dei Tos AP, Garofalo T, Giordano A, Bassi I, Massani M. Rare Neoplasm Mimicking Neuroendocrine Pancreatic Tumor: A Case Report of Solitary Fibrous Tumor with Review of the Literature. **Anticancer Res.** 2017 Jun;**37(6):3093-3097**.

288. Sbaraglia M, Righi A, Gambarotti M, Vanel D, Picci P, Dei Tos AP. Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls. **Surg Pathol Clin.** 2017 Sep;**10(3):705-730**.

289. Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, Dei Tos AP, Simi L, Pinzani P, Franchi A. Histone 3.3 Mutations in Giant Cell Tumor and Giant Cell-Rich Sarcomas of Bone. **Hum Pathol.** 2017 Oct;**68:128-135**.

290. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali PG, Sanfilippo R. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. **Clin Sarcoma Res.** 2017 Aug 22;**7:1**.

291. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. **Br J Cancer.** 2017 Jul 25;**117(3):340-346**.

292. Mandrioli M, Mastrangelo L, Masetti M, Zanini N, Lega S, Nannini M, Gruppioni E, Altissimi A, Dei Tos AP, Fabbri C, Jovine E. Characterization of malignant gastrointestinal stromal tumors-a single center experience. **J Gastrointest Oncol.** 2017 Dec;**8(6):1037-1045**.

## 2018

293. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, Gronchi

A, Reuss DE, von Deimling A, Maestro R, Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. **Mod Pathol.** 2018 Jan;**31(1):160-168.**

294. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, Gronchi A, Reuss DE, von Deimling A, Maestro R, Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. **Mod Pathol.** 2018 Jan;**31(1):160-168.**

295. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llombar-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. **Eur J Cancer.** 2018; **20;93:28-36.**

296. Sambataro M, Sambado L, Trevisiol E, Cacciatore M, Furlan A, Stefani PM, Seganfredo E, Durante E, Conte S, Della Bella S, Paccagnella A, Dei Tos AP. Proinsulin-expressing dendritic cells in type 2 neuropathic diabetic patients with and without foot lesions. **FASEB J.** 2018 Jul;**32(7):3742-3751.**

297. Righi A, Sbaraglia M, Gambarotti M, Cocchi S, Drago G, Casadei R, Picci P, Vanel D, Dei Tos AP. Extra-axial chordoma: a clinicopathologic analysis of six cases. **Virchows Arch** 2018 Jun;**472(6):1015-1020.**

298. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskelatal Myxoid Chondrosarcoma. **Int J Mol Sci.** 2018 Jun **23;19 (7).**

299. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desai IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. **JAMA Oncol.** 2018 Sep **1;4(9):e180219.**

300. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2018 Oct **1;29(Suppl 4):iv68-iv78.**

301. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2018 Oct **1;29(Suppl 4):iv268-iv269.**

302. Dei Tos AP, Bonvalot S, Haas R. The key role of pathology, surgery and radiotherapy in the initial management of soft tissue sarcoma. **Future Oncol.** 2018 May;**14(10s):15-23**.

303. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. **Anticancer Drugs.** 2018;**29:589-595**.

304. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, Gronchi A, Dei Tos AP, Casali PG. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. **ESMO Open.** 2018 Jun **28;3(4)**

305. Nannini M, Dondi G, Santini D, De Leo A, Dei Tos AP, Zamagni C, Saponara M, Gatto L, Nigro C, Bertaccini P, Zompatori M, De Iaco P, Perrone MA, Pantaleo MA. A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. **Clin Med Insights Oncol.** 2018 Jun **18;12**.

306. Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2018 Oct **1;29(Supplement\_4):iv79-iv95**

307. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Casali PG, Wunder JS, Gronchi A. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. **Eur J Cancer.** 2018 Oct **29;105:19-27**.

308. Rossi S, Brenca M, Zanatta L, Trincia E, Guerriero A, Pizzato C, Fiorindi A, Viscardi E, Giangaspero F, Maestro R, Dei Tos AP, Giannini C. A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomas. **J Neuropathol Exp Neurol.** 2018 Oct **1;77(10):883-889**.

309. Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. **Lancet Oncol.** 2018 Oct;**19(10):1360-1371**.

310. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. **Ther Adv Med Oncol.** 2018 Aug;**29;10:1758835918794623**.

311. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G,

Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for Thymic Malignancies (TYME). **Cancer Treat Rev.** 2018 5;71:76-87.

## 2019

312. Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. *Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.* **Lancet Oncol.** 2019 Jan;20(1):134-144.

313. Gambarotti M, Dei Tos AP, Vanel D, Picci P, Gibertoni D, Klein MJ, Righi A. *Osteoblastoma-like osteosarcoma: High-grade or low-grade osteosarcoma?* **Histopathology.** 2019 Feb;74(3):494-503.

314. Sbaraglia M, Dei Tos AP. *The pathology of soft tissue sarcomas.* **Radiol Med.** 2019 Apr;124(4):266-281.

315. Boriani S, Cecchinato R, Righi A, Bandiera S, Dei Tos AP, Ghermandi R, Gasbarrini A. *Primary vascular bone tumors in the spine: a challenge for pathologists and spine oncology surgeons.* **Eur Spine J.** 2019 Jun;28(6):1502-1511.

316. Boriani S, Cecchinato R, Righi A, Bandiera S, Dei Tos AP, Ghermandi R, Gasbarrini A. Correction to: Primary vascular bone tumors in the spine: a challenge for pathologists and spine oncology surgeons. **Eur Spine J.** 2019 Oct;28(10):2433

317. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R. *Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.* **Oncologist** 2019 Jul;24(7):e536-e541.

318. Portelli F, Pieretti G, Santoro N, Gorelli G, De Giorgi V, Massi D, Dei Tos AP, Mazzini C. *Primary Orbital Synovial Sarcoma Mimicking a Periocular Cyst.* **Am J Dermatopathol.** 2019 Sep;41(9):655-660.

319. Frezza AM, Botta L, Trama A, Dei Tos AP, Stacchiotti S; RARECARE Working Group. *Chordoma: update on disease, epidemiology, biology and medical therapies.* **Curr Opin Oncol.** 2019 Mar;31(2):114-120.

320. Trama A, Badalamenti G, Baldi GG, Brunello A, Caira M, Drove N, Marrari A, Palmerini E, Vincenzi B, Dei Tos AP, Grignani G. *Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes.* **Cancer Epidemiol.** 2019; 59:258-264.

321. Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani, Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. *Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.* **Clin Cancer Res.** 2019 Jul 1;25(13):3954-3961.

322. Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group. *The impact of chemotherapy on survival of patients with extremity and trunk wall soft*

tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. **Eur J Cancer.** 2019 Mar;**109**:51-60.

323. Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R. *NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas.* **J Pathol.** 2019 Sep;**249**(1):90-101.

324. Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. *Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.* **EClinicalMedicine.** 2019 Mar **11**;9:35-43.

325. Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. *Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas).* **Clin Cancer Res.** 2019 Sep **1**;25(17):5295-5300.

326. Ruengwanichayakun P, Gambarotti M, Frisoni T, Gibertoni D, Guaraldi F, Sbaraglia M, Dei Tos AP, Picci P, Righi A. *PAROSTEAL osteosarcoma: a monocentric retrospective analysis of 195 patients.* **Hum Pathol.** 2019 Sep;**91**:11-18.

327. Boscolo-Rizzo P, Schroeder L, Sacchetto V, Holzinger D, Da Mosto MC, Tirelli G, Dal Cin E, Mantovani M, Menegaldo A, Del Mistro A, Romeo S, Dei Tos AP, Niero M, Rigo S, Dyckhoff G, Hess J, Alemany L, Quer M, León X, Polesel J, Pawlita M, Bertorelle R. *Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma of unknown primary.* **Head Neck.** 2019 Nov;**41**(11):3833-3841.

328. Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N. *Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.* **Cancers (Basel).** 2019 Jul **19**;11(7):1015.

329. Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. *Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.* **J Immunother Cancer.** 2019 Nov **8**;7(1):297.

330. Cesare Ruffolo, Luisa Toffolatti, Marco Massani, Anna Pozza, Marta Campo Dell'Orto, Luca M Saadeh, Francesco Ferrara, Stefano Benvenuti, Angelo P Dei Tos, Nicolò Bassi, Andromachi Kotsafti, Marco Scarpa. *Interferon-Gamma and Tumor Necrosis Factor-Related Weak Inducer of Apoptosis Expression in Neoangiogenesis in Colorectal Polypoid Lesions.* **Eur Surg Res.** 2019;**60**(5-6):186-195

## 2020

331. Sbaraglia M, Righi A, Gambarotti M, Dei Tos AP. *Ewing sarcoma and Ewing-like tumors.* **Virchows Arch.** 2020 Jan;**476**(1):109-119.

332. Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, Lombardi P, Filippi R, Spallanzani A, Cascinu S, Bonetti LR, Maddalena G, Valeri N, Sottoriva A, Zapata L, Salmaso R, Munari G, Rugge M, Dei Tos AP, Golovato J, Sanborn JZ, Nguyen A, Schirripa M, Zagonel V, Lonardi S, Fassan M.



*Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist. 2020; 25(6):481-487*

333. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. *Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open. 2020 Jan;5(1):e000604.*

334. Boscolo-Rizzo P, Giunco S, Rampazzo E, Brutti M, Spinato G, Menegaldo A, Stellin M, Mantovani M, Bandolin L, Rossi M, Del Mistro A, Tirelli G, Dei Tos AP, Guerriero A, Niero M, Da Mosto MC, Polesel J, De Rossi A. *TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2020 Feb;146(2):381-389.*

335. Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, Guercio M, Milano GM, Tamborini E, Busico A, Dagrada G, Garofalo C, Caruso C, Brunello A, Pignochino Y, Berrino E, Grignani G, Scotlandi K, Parra A, Hattinger CM, Ibrahim T, Mercatali L, De Vita A, Carriero MV, Pallocca M, Loria R, Covello R, Sbaraglia M, Dei Tos AP, Falcioni R, Maestro R. *Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. Front Oncol. 2020 Apr 15;10:489.*

336. Frezza AM, Sbaraglia M, Lo Vullo S, Baldi GG, Simeone N, Frenos F, Campanacci D, Stacchiotti S, Pasquali S, Callegaro D, Gambarotti M, Barisella M, Palomba A, Mariani L, Casali PG, Dei Tos AP, Gronchi A. *The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. EJSO 2020, 46(7):1320-1326*

337. Dei Tos AP, Bonvalot S, Haas R. *Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy. Expert Rev Anticancer Ther. 2020 Apr 29:1-11.*

338. Righi A, Sbaraglia M, Gambarotti M, Gibertoni D, Rovira MP, Benini S, Errani C, Brenca M, Maestro R, Dei Tos AP. *Primary Vascular Tumors of Bone: Monoinstitutional Morphologic and Molecular Analysis of 427 Cases With Emphasis on Epithelioid Variants. Am J Surg Pathol. 2020 Sep;44(9):1192-1203.*

339. Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, Italiano A, Sargos P, Cruz-Jurado J, Isern-Verdum J, Dolado MC, Rincon-Pérez I, Sanchez-Bustos P, Gutierrez A, Romagosa C, Morosi C, Grignani G, Gatti M, Luna P, Alastuey I, Redondo A, Belinchon B, Martinez-Serra J, Sunyach MP, Coindre JM, Dei Tos AP, Romero J, Gronchi A, Blay JY, Moura DS. *Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA Oncol. 2020 Feb 20;6(4):535-41.*

340. Panciera T, Citron A, Di Biagio D, Battilana G, Gandin A, Giulitti S, Forcato M, Bicciato S, Panzetta V, Fusco S, Azzolin L, Totaro A, Dei Tos AP, Fassan M, Vindigni V, Bassetto F, Rosato A, Brusatin G, Cordenonsi M, Piccolo S. *Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties. Nat Mater. 2020 19(7):797-806.*

341. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. *Pan-cancer analysis of whole genomes. Nature. 2020; 578(7793):82-93.*

342. Desmoid Tumor Working Group. *The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020; 127:96-107.*

343. Radaelli S, Fossati P, Stacchiotti S, Akiyama T, Asencio JM, Bandiera S, Boglione A, Boland P, Bolle S, Bruland Ø, Brunello A, Bruzzi P, Campanacci D, Cananzi F, Capanna R, Casadei R, Cordoba A, Court C, Dei Tos AP, DeLaney TF, De Paoli A, De Pas TM, Desai A, Di Brina L, Donati DM, Fabbri N, Fiore MR, Frezza A, Gambarotti M, Gasbarrini A, Georg P, Grignani G, Hindi N, Hug EB, Jones R, Kawai A, Krol AD, Le Grange F, Luzzati A, Marquina G, Martin-Benlloch JA, Mazzocco K, Navarra F, Navarra P, Parchi PD, Patel S, Pennacchioli E, Petrongari MG, Picci P, Pollock R, Porcu L, Quagliuolo V, Sangalli C, Scheipl S, Scotto GM, Spalek M, Steinmeier T, Timmermann B, Trama A, Uhl M, Valverde C, Varga PP, Verges R, Weber DC, Zoccali C, Casali PG, Sommer J, Gronchi A. *The sacral chordoma margin*. **Eur J Surg Oncol.** 2020 Aug;**46(8):1415-1422**

344. Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, Martín J, Patel S, Penault-Llorca F, Premanand Raut C, Rutkowski P, Safwat A, Sbaraglia M, Schaefer IM, Shen L, Serrano C, Schöffski P, Stacchiotti S, Sundby Hall K, Tap WD, Thomas DM, Trent J, Valverde C, van der Graaf WTA, von Mehren M, Wagner A, Wardelmann E, Naito Y, Zalcberg J, Blay JY. *Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network*. **Ann Oncol.** 2020 Sep 3;**S0923-7534(20)42297-5**.

345. Schirripa M, Nappo F, Cremonini C, Salvatore L, Rossini D, Bensi M, Businello G, Pietrantonio F, Randon G, Fucà G, Boccaccino A, Bergamo F, Lonardi S, Dei Tos AP, Fassan M, Loupakis F. *KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population*. **Clin Colorectal Cancer.** 2020 Sep;**19(3):219-225**

346. Ruffolo C, Ferrara F, Trevellin E, Cataldo I, Fornasier C, Pozza A, Campo Dell'Orto M, Angriman I, Dei Tos AP, Bardini R, Massani M, Kotsafti A, Scarpa M. *Can Vascular Endothelial Growth Factors and CD34 Expression Implement NICE (Narrow-Band Imaging International Colorectal Endoscopic) Classification in Colorectal Polypoid Lesion Diagnosis?* **Eur Surg Res.** 2020 Oct **20:1-11**

347. Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. *Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial*. **Lancet Oncol.** 2020 Oct;**21(10):1366-1377**

348. Casali PG, Dei Tos AP, Gronchi A. *When does a new sarcoma exist?* **Clin Sarcoma Res.** 2020 Sep **13:10:19**

349. Benedetta Chiusole, Axel Le Cesne, Marco Rastrelli, Marco Maruzzo , Martina Lorenzi , Rocco Cappellesso , Paolo Del Fiore, Silvia Imbevaro, Marta Sbaraglia , Philippe Terrier, Pietro Ruggieri , Angelo Paolo Dei Tos, Carlo Riccardo Rossi , Vittorina Zagonel, Antonella Brunello. *Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions*. **Front Oncol.** 2020 Jun **16;10:828**.

350. Cristina Basso, Fiorella Calabrese, Marta Sbaraglia, Claudia Del Vecchio, Giovanni Carretta, Annamaria Saieva, Daniele Donato, Luciano Flor, Andrea Crisanti, Angelo Paolo Dei Tos. *Feasibility of postmortem examination in the era of COVID-19 pandemic: the experience of a Northeast Italy University Hospital*. **Virchows Arch.** 2020 Sep;**477(3):341-347**

351. Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. *Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors*. **Clin Cancer Res.** 2020 Oct **15;26(20):5534-5538**.

352. Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, Simonelli M,

Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. *Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study*. **Cancers (Basel)**. 2020 Aug 14;12(8):2283

353. Marco Gambarotti, Marina Pacheco, Poosit Ruengwanichayakun , Brayán Silvano Vega Jiménez, Stefania Benini, Giuseppe Bianchi , Marta Sbaraglia, Daniel Vanel , Elisa Carretta, Franco Bertoni , Alessandro Franchi , Angelo P Dei Tos, Alberto Righi. *Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature*. **Histopathology**, 2020 Sep;77(3):391-401.

354. Gronchi A, Palmerini E, Quagliuolo V, Martín Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. *Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups*. **J Clin Oncol**. 2020 Jul 1;38(19):2178-2186.

355. Elisabetta Di Liso, Michele Bottosso, Marcello Lo Mele, Vassilena Tsvetkova, Maria Vittoria Dieci,, Federica Miglietta, Cristina Falci, Giovanni Faggioni, Giulia Tasca, Carlo Alberto Giorgi, Tommaso Giarratano, Eleonora Mioranza, Silvia Michieletto, Tania Saibene, Angelo Paolo Dei Tos 3, PierFranco Conte, Valentina Guarneri. *Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases*. **ESMO Open**. 2020 Oct;5(5):e000843

356. Gabriella Ferrandina, Cynthia Aristei, Pietro Raimondo Biondetti, Ferdinando Carlo Maria Cananzi , Paolo Casali , Francesca Ciccarone , Nicoletta Colombo , Alessandro Comandone , Renzo Corvo', Pierandrea De Iaco , Angelo Paolo Dei Tos , Vittorio Donato , Marco Fiore , Franchi , Angiolo Gadducci , Alessandro Gronchi , Stefano Guerriero , Amato Infante , Franco Odicino , Tommaso Pirroni , Vittorio Quagliuolo , Roberta Sanfilippo , Antonia Carla Testa , Gian Franco Zannoni , Giovanni Scambia , Domenica Lorusso. *Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)* **Eur J Cancer**, 2020 Nov;139:149-168

357. Mammana M, Bergamo F, Procaccio L, Schiavon M, Loupakis F, Lonardi S, Manai C, Schirripa M, Fassan M, Dei Tos AP, Calabrese F, Rea F, Zagonel V. *Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis*. **Tumori**. 2021 Feb;107(1):46-54 .

358. Baldi GG, Brahmi M, Lo Vullo S, Cojocarú E, Mir O, Casanova M, Vincenzi B, De Pas TM, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, Casali PG, Stacchiotti S. *The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis*. **Oncologist**. 2020 Nov;25 (11):e1777-e1784

359. Gasparotto D, Sbaraglia M, Rossi S, Baldazzi D, Brenca M, Mondello A, Nardi F, Racanelli D, Cacciatore M, Dei Tos AP, Maestro R. *Tumor genotype, location and malignant potential shape the immunogenicity of primary, untreated Gastrointestinal Stromal Tumors*. **JCI Insight**. 2020 Oct 13:142560. doi: 10.1172/jci.insight.142560. Online ahead of print.

360. Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, Guercio M, Milano GM, Tamborini E, Busico A, Dagrada G, Garofalo C, Caruso C, Brunello A, Pignochino Y, Berrino E, Grignani G, Scotlandi K, Parra A, Hattinger CM, Ibrahim T, Mercatali L, De Vita A, Carriero MV, Pallocca M, Loria R, Covello R, Sbaraglia M, Dei Tos AP, Falcioni R, Maestro R. *Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group*. **Front Oncol**. 2020 Jun 23;10:944.

2021

361. Sbaraglia M, Bellan E, Dei Tos AP. *The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives*. **Pathologica**. 2021 Apr;**113(2):70-84**.

362. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. *Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up*. **Ann Oncol**. 2021 Nov;**32(11):1348-1365**.

363. Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, Criscitiello C, Vigneri P, Dei Tos AP, Maiorano E, Viale G. *PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer*. **Front Oncol**. 2021 Mar **25;11:644737**.

364. Valeria Tosello, Deborah Bongiovanni , Jingjing Liu , Qingfei Pan , Koon-Kiu Yan , Valentina Saccomani , Maaïke Van Trimpont , Marco Pizzi, Martina Mazzoni, Angelo Paolo Dei Tos , Alberto Amadori , Paola Zanollo , Pieter Van Vlierbergh, Jiyang Yu , Erich Piovan. *Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination*. **Leukemia**. 2021 Apr;**35(4):984-1000**

365. Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia Del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, López Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. *Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up*. **Ann Oncol**. 2021 Dec;**32(12):1520-1536**.

366. Sbaraglia M, Gambarotti M, Businello G, Righi A, Fassan M, Dei Tos AP. *Intra-Articular Tumors*. **Surg Pathol Clin**. 2021 Dec;**14(4):665-677**.

367. Zarrilli G, Angerilli V, Businello G, Sbaraglia M, Traverso G, Fortarezza F, Rizzo S, De Gaspari M, Basso C, Calabrese F, Dei Tos AP, Fassan M. *The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury*. **Int J Mol Sci**. 2021 Jan **19;22(2):974**.

368. Menegaldo A, Schroeder L, Holzinger D, Tirelli G, Dal Cin E, Tofanelli M, Rigo S, Mantovani M, Stellin M, Del Mistro A, Dei Tos AP, Guerriero A, Niero M, Borsetto D, Da Mosto MC, Polesel J, Pawlita M, Waterboer T, Boscolo-Rizzo P. *Detection of HPV16/18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay*. **Laryngoscope**. 2021 May;**131(5):1042-1048**.

369. Sbaraglia M, Businello G, Bellan E, Fassan M, Dei Tos AP. *Mesenchymal tumours of the*

*gastrointestinal tract. Pathologica. 2021 Jun;113(3):230-251.*

370. Righi A, Pacheco M, Pipola V, Gambarotti M, Benini S, Sbaraglia M, Frisoni T, Boriani S, Dei Tos AP, Gasbarrini A. *Primary sclerosing epithelioid fibrosarcoma of the spine: a single-institution experience. Histopathology. 2021 Jun;78(7):976-986.*

371. Sbaraglia M, Zanatta L, Toffolatti L, Spallanzani A, Bertolini F, Mattioli F, Lami F, Presutti L, Dei Tos AP. *Clear cell sarcoma-like/malignant gastrointestinal neuroectodermal tumor of the tongue: a clinicopathologic and molecular case report. Virchows Arch. 2021 Jun;478(6):1203-1207*

372. Pizzi M, Agostinelli C, Santoro L, Sbaraglia M, Bertuzzi C, Dal Santo L, Friziero A, Piazza F, Zinzani PL, Dei Tos AP, Sabattini E. *Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. Eur J Haematol. 2021 May;106(5):737-739.*

373. Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A. *Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021 Jun 2;6(3):100170.*

374. Tosi A, Cappellesso R, Dei Tos AP, Rossi V, Aliberti C, Pigozzo J, Fabozzi A, Sbaraglia M, Blandamura S, Del Bianco P, Chiarion-Sileni V, Rosato A. *The immune cell landscape of metastatic uveal melanoma correlates with overall survival. J Exp Clin Cancer Res. 2021 May 4;40(1):154.*

375. Gambarotti M, Erdogan KE, Righi A, Benini S, Raspollini MR, Rose AD, Magagnoli G, Sbaraglia M, Dei Tos AP. *Lipoblastoma-like tumor of the spermatic cord: case report and review of the literature. Virchows Arch. 2021 May;478(5):1013-1017.*

376. Bianchi G, Lana D, Gambarotti M, Ferrari C, Sbaraglia M, Pedrini E, Pazzaglia L, Sangiorgi L, Bartolotti I, Dei Tos AP, Scotlandi K, Righi A. *Clinical, Histological, and Molecular Features of Solitary Fibrous Tumor of Bone: A Single Institution Retrospective Review. Cancers (Basel). 2021 May 19;13(10):2470.*

377. Munari G, Businello G, Mattiolo P, Pennelli G, Sbaraglia M, Borgia C, Pucciarelli S, Spolverato G, Mescoli C, Galuppini F, Sommariva A, Bellan E, Lonardi S, Loupakis F, Luchini C, Dei Tos AP, Fassan M. *Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. J Cancer Res Clin Oncol. 2021 Jul;147(7):1897-1904.*

378. Pizzi M, Friziero A, Vianello F, Binotto G, Da Dalt G, Zoletto S, Carraro E, Fassan M, Sbaraglia M, Sperti C, Baldan N, D'Amore F, Bertozzi I, Righi S, Pierobon ES, Moletta L, Capovilla G, Grego A, Sabattini E, Fabris F, Merigliano S, Dei Tos AP. *Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications. Eur J Haematol. 2021 Feb;106(2):281-289.*

379. Pizzi M, Sbaraglia M, Bellan A, Santoro L, Dal Santo L, De Bartolo D, Carraro E, Zoletto S, Visentin A, Marino D, Trentin L, Dei Tos AP. *Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations. Virchows Arch. 2021 Apr 8. doi: 10.1007/s00428-021-03096-4. Online ahead of print.*

380. Righi A, Pacheco M, Palmerini E, Carretta E, Gambarotti M, Longhi A, Magagnoli G, Sbaraglia M, Manfrini M, Picci P, Dei Tos AP. *Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools*. **Eur J Surg Oncol**. 2021 Feb 16;S0748-7983(21)00100-1.
381. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. *Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities*. **Cancer**. 2021 Aug 15;127(16):2934-2942
382. Erdogan KE, Pacheco M, Gambarotti M, Magagnoli G, Sbaraglia M, Frisoni T, Righi A, Dei Tos AP. *Usefulness of  $\beta$ -catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma*. **Virchows Arch**. 2021 Sep;479 (3):529-535
383. Pizzi M, Agostinelli C, Santoro L, Sbaraglia M, Bertuzzi C, Dal Santo L, Friziero A, Piazza F, Zinzani PL, Dei Tos AP, Sabattini E. *Lymph node core needle biopsy in lymphoproliferative disorders-Authors' reply to Al-Abadi and colleagues*. **Eur J Haematol**. 2021 Aug;107(2):297-298
384. Fassan M, Mescoli C, Sbaraglia M, Guzzardo V, Russo FP, Fabris R, Trevenzoli M, Pelizzaro F, Cattelan AM, Basso C, Navalesi P, Farinati F, Vettor R, Dei Tos AP. *Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens*. **Pathol Res Pract**. 2021 May;221:153451.
385. Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, Palassini E, Dagrada G, Collini P, Morosi C, Greco FG, Sbaraglia M, Dei Tos AP, Mariani L, Frezza AM, Casali PG. *Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network*. **Cancer**. 2021 Feb 15;127(4):569-576
386. Mafficini A, Lawlor RT, Ghimenton C, Antonello D, Cantù C, Paolino G, Nottegar A, Piredda ML, Salvia R, Milella M, Dei Tos AP, Fassan M, Scarpa A, Luchini C. *Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling*. **Genes (Basel)**. 2021 Mar 26;12(4):481.
387. Borga C, Dal Pozzo CA, Trevellin E, Bergamo F, Murgioni S, Milanetto AC, Pasquali C, Cillo U, Munari G, Martini C, De Carlo E, Zagonel V, Guzzardo V, Pennelli G, Dei Tos AP, Vettor R, Fassan M. *mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs*. **Endocr Relat Cancer**. 2021 Jun 10;28(7):449-456.
388. Cappellesso R, Nozzoli F, Zito Marino F, Simi S, Castiglione F, De Giorgi V, Cota C, Senetta R, Scognamiglio G, Anniciello AM, Cesinaro AM, Mandalà M, Gianatti A, Valente MG, Valeri B, Sementa AR, Ricci C, Corti B, Roviello G, Dei Tos AP, Franco R, Massi D. *NTRK Gene Fusion Detection in Atypical Spitz Tumors*. **Int J Mol Sci**. 2021 Nov 15;22(22):12332.
389. Scarpa M, Ruffolo C, Kotsafti A, Canal F, Erroi F, Basato S, Dall'Agnese L, Fiorot A, Pozza A, Brun P, Bassi N, Dei Tos A, Castoro C, Castagliuolo I, Scarpa M. *MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer*. **Front Mol Biosci**. 2021 May 7;8:624873.
390. Angerilli V, Fontana E, Lonardi S, Sbaraglia M, Borelli B, Munari G, Salmaso R, Guzzardo V, Spolverato G, Pucciarelli S, Pilati P, Hahne JC, Bergamo F, Zagonel V, Dei Tos AP, Sadanandam A,

Loupakis F, Valeri N, Fassan M. *Intratumor morphologic and transcriptomic heterogeneity in V600E BRAF-mutated metastatic colorectal adenocarcinomas*. **ESMO Open**. 2021 Aug;6(4):100211.

391. Calabrese F, Fortarezza F, Pezzuto F, Lunardi F, Comacchio G, Sbaraglia M, Pasello G, Marulli G, Dei Tos AP, Rea F. *The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience*. **Cancers (Basel)**. 2021 Aug 12;13(16):4056.

392. Manni S, Fregnani A, Quotti Tubi L, Spinello Z, Carraro M, Scapinello G, Visentin A, Barilà G, Pizzi M, Dei Tos AP, Vianello F, Zambello R, Gurrieri C, Semenzato G, Trentin L, Piazza F. *Protein Kinase CK1 $\alpha$  Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma*. **Front Oncol**. 2021 Oct 14;11:733848.

393. Righi L, Righi A, Vatrano S, Rapa I, Listi A, Metovic J, Rocca M, Salone M, Giovenali P, Sidoni A, Tabbò F, Dei Tos AP, Volante M, Papotti M. *Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas*. **Virchows Arch**. 2021 Jun;478(6):1125-1134.

394. Elefanti L, Zamuner C, Del Fiore P, Stagni C, Pellegrini S, Dall'Olmo L, Fabozzi A, Senetta R, Ribero S, Salmaso R, Mocellin S, Bassetto F, Cavallin F, Tosi AL, Galuppini F, Dei Tos AP, Menin C, Cappellesso R. *The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)*. **Int J Mol Sci**. 2021 Apr 7;22(8):3826.

395. Sbaraglia M, Bellan E, Mentzel T, Dei Tos AP. *The contribution of Juan Rosai to the pathology of soft tissue tumors*. **Pathologica**. 2021 Oct;113(5):396-409.

396. Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP, Sabattini E, Gianelli U. *The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases*. **Cancers (Basel)**. 2021 Nov 12;13(22):5666.

397. Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Biason P, Borga C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakis F. *Synaptophysin expression in V600EBRAF- mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis*. **Eur J Cancer**. 2021 Mar;146:145-154.

398. Menegaldo A, Schroeder L, Holzinger D, Tirelli G, Dal Cin E, Tofaneli M, Rigo S, Mantovani M, Stellin M, Del Mistro A, Dei Tos AP, Guerriero A, Niero M, Borsetto D, Da Mosto MC, Polesel J, Pawlita M, Waterboer T, Boscolo-Rizzo P. *Detection of HPV16/18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay*. **Laryngoscope**. 2021 May;131(5):1042-1048.

399. Del Fiore P, Russo I, Ferrazzi B, Monico AD, Cavallin F, Filoni A, Tropea S, Russano F, Di Prata C, Buja A, Collodetto A, Spina R, Carraro S, Cappellesso R, Nicolè L, Chiarion-Sileni V, Pigozzo J, Dall'Olmo L, Rastrelli M, Vecchiato A, Benna C, Menin C, Di Carlo D, Bisogno G, Dei Tos AP, Alaibac M, Mocellin S. *Melanoma in Adolescents and Young Adults: Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study*. **Front Oncol**. 2021 Sep 16;11:725523.

400. Nicolè L, Cappello F, Cappellesso R, Piccin L, Ventura L, Guzzardo V, Del Fiore P, Chiarion-Sileni V, Dei Tos AP, Mocellin S, Fassina A. *RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study*. **Front Oncol**. 2021 Oct 21;11:728319.

401. Giacometti C, Bellan E, Ambrosi A, Dei Tos AP, Cassaro M, Ludwig K. "While there is p57, there is hope." *The past and the present of diagnosis in first trimester abortions: Diagnostic dilemmas and*

*algorithmic approaches. A review. Placenta. 2021 Dec;116:31-37.*

402. Giunco S, Boscolo-Rizzo P, Rampazzo E, Tirelli G, Alessandrini L, Di Carlo R, Rossi M, Nicolai P, Menegaldo A, Carraro V, Tofanelli M, Bandolin L, Spinato G, Emanuelli E, Mantovani M, Stellin M, Bussani R, Dei Tos AP, Guido M, Morello M, Fussey J, Esposito G, Polesel J, De Rossi A. TERT Promoter Mutations and rs2853669 Polymorphism: Useful Markers for Clinical Outcome Stratification of Patients With Oral Cavity Squamous Cell Carcinoma. **Front Oncol. 2021 Nov 10;11:782658.**

403. Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F, Spolverato G, Pucciarelli S, Merigliano S, Pilati P, Cavallin F, Realdon S, Farinati F, Dei Tos AP, Zagonel V, Lonardi S, Loupakis F, Fassan M. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. **J Pers Med. 2021 Oct 26;11(11):1095.**

404. Di Battista P, Lovisa F, Gaffo E, Galligani I, Damanti CC, Garbin A, Ferrone L, Carraro E, Pillon M, Lo Nigro L, Mura R, Pizzi M, Guzzardo V, Dei Tos AP, Biffi A, Bortoluzzi S, Mussolin L. Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology. **Front Oncol. 2021 May 25;11:663221.**

405. Rastrelli M, Del Fiore P, Russo I, Tartaglia J, Dal Monico A, Cappellesso R, Nicolè L, Piccin L, Fabozzi A, Biffoli B, Di Prata C, Ferrazzi B, Dall'Olmo L, Vecchiato A, Spina R, Russano F, Bezzon E, Cingarlini S, Mazzarotto R, Parisi A, Scarzello G, Pigozzo J, Brambullo T, Tropea S, Vindigni V, Bassetto F, Bertin D, Gregianin M, Dei Tos AP, Cavallin F, Alaibac M, Chiarion-Sileni V, Mocellin S. Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). **Front Oncol. 2021 Dec 17;11:737842.**

406. Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STSS 1001 Randomized Phase III Trial. **Mol Cancer Ther. 2021 Dec;20(12):2539-2552.**

407. Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. **J Exp Clin Cancer Res. 2021 Mar 1;40(1):83.**

408. Ziranu P, Lai E, Schirripa M, Puzzone M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. **Target Oncol. 2021 Jul;16(4):517-527.**

409. Del Fiore P, Russo I, Ferrazzi B, Monico AD, Cavallin F, Filoni A, Tropea S, Russano F, Di Prata C, Buja A, Collodetto A, Spina R, Carraro S, Cappellesso R, Nicolè L, Chiarion-Sileni V, Pigozzo J, Dall'Olmo L, Rastrelli M, Vecchiato A, Benna C, Menin C, Di Carlo D, Bisogno G, Dei Tos AP, Alaibac M, Mocellin S. Corrigendum: Melanoma in Adolescents and Young Adults (AYA): Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study. **Front Oncol. 2021 Oct 27;11:793169.**

410. Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guameri V, Pierini A, Amunni G, Conte P. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. **ESMO Open. 2021 Apr;6(2):100040.**



411. Del Fiore P, Rastrelli M, Dall'Olmo L, Cavallin F, Cappellesso R, Vecchiato A, Buja A, Spina R, Parisi A, Mazzarotto R, Ferrazzi B, Grego A, Rotondi A, Benna C, Tropea S, Russano F, Filoni A, Bassetto F, Dei Tos AP, Alaibac M, Rossi CR, Pigozzo J, Chiarion Sileni V, Mocellin S. *Corrigendum: Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study*. **Front Oncol.** 2021 Apr 14;11:686051.

412. Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, Colombo N, Comandone A, Corvo' R, De Iaco P, Dei Tos AP, Donato V, Fiore M, Franchi, Gadducci A, Gronchi A, Guerriero S, Infante A, Odicino F, Pirroni T, Quagliuolo V, Sanfilippo R, Testa AC, Zannoni GF, Scambia G, Lorusso D. *Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168]*. **Eur J Cancer.** 2021 Feb;144:397-398.

## 2022

413. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. *Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up*. **Ann Oncol.** 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21.

414. Galuppini F, Censi S, Merante Boschin I, Fassan M, Sbaraglia M, Valeri N, Hahne JC, Bertazza L, Munari G, Galasso M, Cascione L, Barollo S, Ruggie M, Vianello F, Dei Tos AP, Mian C, Pennelli G. *Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling*. **Front Endocrinol (Lausanne).** 2022 Feb 23;13:834075. doi: 10.3389/fendo.2022.834075.

415. Righi A, Gambarotti M, Benini S, Gibertoni D, Asioli S, Magagnoli G, Gamberi G, Sbaraglia M, Cocchi S, Staals E, Palmerini E, Dei Tos AP. *Primary synovial sarcoma of bone: a retrospective analysis of 25 patients*. **Histopathology.** 2022 Mar;80(4):686-697. doi: 10.1111/his.14602. Epub 2022 Jan 18.

416. Blay JY, Hindi N, Bollard J, Aguiar S Jr, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. *SELNET clinical practice guidelines for soft tissue sarcoma and GIST*. **Cancer Treat Rev.** 2022 Jan;102:102312. doi: 10.1016/j.ctrv.2021.102312. Epub 2021 Nov 14.

417. Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz-Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG, Gronchi A. *Neoadjuvant*

chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-ST5 1001 randomized trial. **Cancer**. 2022 Jan 1;128(1):85-93. doi: 10.1002/cncr.33895. Epub 2021 Oct 13. Erratum in: **Cancer**. 2022 Sep 1;128(17):3265.

418. Angriman I, Fassan M, Nacci C, De Simoni O, Kotsafti A, Businello G, Ruffolo C, Scarpa M, Dei Tos AP, Agostini M, Pucciarelli S, Bardini R, Scarpa M. *Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions*. **Surgery**. 2022 Jun;171(6):1605-1611. doi: 10.1016/j.surg.2021.12.005. Epub 2022 Jan 6.

419. Pizzi M, Sbaraglia M, De Bartolo D, Dal Santo L, Santoro L, Faedo A, Cecchetto M, Dei Tos AP. *Beware of Histiocytes: Whipple Adenopathy and its Mimics*. **Int J Surg Pathol**. 2022 Apr;30(2):163-166. doi:10.1177/10668969211026370. Epub 2021 Jun 18.

420. Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M. *Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study*. **Eur J Cancer**. 2022 Mar 15;166:165-175. doi:10.1016/j.ejca.2022.02.013. Epub 2022 Mar 15.

421. Angerilli V, Galuppini F, Pennelli G, Fanelli GN, d'Amore ESG, Michelotto M, Pilati P, Spolverato G, Pucciarelli S, Scarpa M, Farinati F, Savarino E, Realdon S, Lonardi S, Bergamo F, Loupakis F, Dei Tos AP, Vanoli A, Fassan M. *Epstein-Barr virus associated gastric dysplasia: a new rare entity?* **Virchows Arch**. 2022 Apr;480(4):939-944. doi: 10.1007/s00428-021-03206-2. Epub 2021 Sep 19.

422. Fabbroni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. *Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin*. **Cancers (Basel)**. 2021 Mar 22;13(6):1453.

423. Gambarotti M, Righi A, Sbaraglia M, Cocchi S, Benini S, Magagnoli G, Frisoni T, Palmerini E, Picci P, Dei Tos AP. *Primary malignant peripheral nerve sheath tumors of bone: a clinicopathologic reappraisal of 8 cases*. **Hum Pathol**. 2022 Apr;122:92-102. doi: 10.1016/j.humpath.2022.02.003. Epub 2022 Feb 15.

424. Marino D, Pizzi M, Kotova I, Schmidt R, Schröder C, Guzzardo V, Talli I, Peroni E, Finotto S, Scapinello G, Dei Tos AP, Piazza F, Trentin L, Zagonel V, Piovon E. *High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients*. **Cancers (Basel)**. 2022 Jan 11;14(2):338. doi: 10.3390/cancers14020338.

425. Pizzi M, Sbaraglia M, Bellan A, Santoro L, Dal Santo L, De Bartolo D, Carraro E, Zoletto S, Visentin A, Marino D, Trentin L, Dei Tos AP. *Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations*. **Virchows Arch**. 2022 Feb;480(2):459-465. doi: 10.1007/s00428-021-03096-4. Epub 2021 Apr 8.

426. Angotzi F, Visentin A, Scarmozzino F, Cellini A, Bertorelle R, Pizzi M, Binotto G, Dei Tos AP, Trentin L. *Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases*. **Curr Oncol**. 2022 Feb 27;29(3):1455-1460. doi: 10.3390/currenco129030122.

427. Fassan M, Collesei A, Angerilli V, Sbaraglia M, Fortarezza F, Pezzuto F, De Gaspari M, Businello G, Moni M, Rizzo S, Traverso G, Colosso V, Taschin E, Lunardi F, Valls AF, Schiavi F, Basso C, Calabrese F, Dei Tos AP. *Multi-Design Differential Expression Profiling of COVID-19 Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory Pathways and SFTPC Impaired Transcription*. **Cells**. 2022 Mar 16;11(6):1011. doi: 10.3390/cells11061011.

428. Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. *Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study*. **Clin Cancer Res.** 2022 Apr 14;28(8):1672-1679. doi: 10.1158/1078-0432.CCR-21-1665.

429. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calìo A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Ferris R, Antonelli A. *Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study*. **J Pers Med.** 2022 Apr 30;12(5):727. doi:10.3390/jpm12050727.

430. Del Fiore P, Russo I, Dal Monico A, Tartaglia J, Ferrazzi B, Mazza M, Cavallin F, Tropea S, Buja A, Cappellesso R, Nicolè L, Chiarion-Sileni V, Menin C, Vecchiato A, Dei Tos AP, Alaibac M, Mocellin S. *Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study*. **Life (Basel).** 2022 May 17;12(5):745. doi: 10.3390/life12050745.

431. Zarrilli G, Angerilli V, Cappellesso R, Galuppini F, Pennelli G, Farinati F, Nicolè L, Savarino E, Realdon S, Griguolo G, Bottosso M, Dieci MV, Guameri V, Dei Tos AP, Lo Mele M, Fassan M. *Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series*. **Pathol Res Pract.** 2022 May;233:153872. doi: 10.1016/j.prp.2022.153872. Epub 2022 Apr 1.

432. Pizzi M, Sbaraglia M, De Bartolo D, Dal Santo L, Binotto G, Tosato F, Pravato S, Scapinello G, Martines A, Bonaldi L, Dei Tos AP. *Relevance of bone marrow histology in challenging cases of Acute Myeloid Leukemia*. **J Lab Hematol.** 2022 Jun;44(3):e107-e110. doi: 10.1111/ijlh.13750. Epub 2021 Nov 1.

433. Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Chs CS, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden 5th, Chacón M, Clara-Altamirano MA, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati DM, Dufresne A, Eriksson M, Farias-Loza M, Frezza AM, Frisoni T, Garcia-Ortega DY, Gerderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Hindi N, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopes David BB, Lopez-Pousa A, Lutter G, Maki RG, Martinez-Said H, Martinez-Tlahuel JL, Mello CA, Morales Pérez JM, Moura DS, Nakagawa SA, Nascimento AG, Ortiz-Cruz EJ, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Santos TG, Scotlandi K, Mlg S, Soulé T, Stacchiotti S, Valverde CM, Waisberg F, Zamora Estrada E, Martin-Broto J. *SELNET clinical practice guidelines for bone sarcoma*. **Crit Rev Oncol Hematol.** 2022 Jun;174:103685. Epub 2022 Apr 21. Erratum in: **Crit Rev Oncol Hematol.** 2022 Dec;180:103827.

434. Spada F, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quagliano P, Queirolo P, Ascierto PA; DELPHI Panel Members. *Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel*. **J Immunother Cancer.** 2022 Jun;10(6):e004742. doi:10.1136/jitc-2022-004742. Erratum in: **J Immunother Cancer.** 2022 Sep;10(9).

435. Ruge M, Buja A, Tropea S, Girardi G, Franzese LC, Cozzolino C, Zorzi M, Vecchiato A, Del Fiore P, Brunello A, Brazzale AR, Baldo V, Dei Tos AP, Rossi CR, Mocellin S. *Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study*. **Cancers (Basel).** 2022 Jun

24;14(13):3109. doi:10.3390/cancers14133109.

436. Gros L, Dei Tos AP, Jones RL, Digkila A. *Inflammatory Myofibroblastic Tumour: State of the Art*. **Cancers (Basel)**. 2022 Jul 27;14(15):3662. doi:10.3390/cancers14153662.

437. Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bagué S, Dei Tos AP, Braglia L, Palmerini E, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Beveridge RD, Lugowska I, Lesluyes T, Maestro R, Merlo FD, Casali PG, Gronchi A. *CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study*. **Cancer Med**. 2022 Jul 18. doi: 10.1002/cam4.5015. Online ahead of print.

438. Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldì E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D'Ambrosio L, Bardelli A, Pignochino Y, Grignani G. *DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination*. **Front Oncol**. 2022 Aug 30;12:844250. doi: 10.3389/fonc.2022.844250.

439. Pacheco M, Barra L, Gambarotti M, Magagnoli G, Sbaraglia M, Asioli S, Cocchi S, Carretta E, Frisoni T, Benini S, Dei Tos AP, Righi A. *Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis*. **Eur J Surg Oncol**. 2022 Aug;48(8):1730-1738. doi: 10.1016/j.ejso.2022.05.024. Epub 2022 Jun 3.

440. Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. *Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments*. **Cancer Treat Rev**. 2022 Aug 18;110:102455. doi: 10.1016/j.ctrv.2022.102455. Epub 2022 Aug 18.

441. Pizzi M, Binotto G, Rigoni Savioli G, Dei Tos AP, Orazi A. *Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy*. **Br J Haematol**. 2022 Sep;198(6):943-952. doi: 10.1111/bjh.18206. Epub 2022 May 5.

442. Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, Nichele I, Sbaraglia M, Zoletto S, Scarmozzino F, Bresciani R, d'Amore F, Friziero A, Guzzardo V, Bertozzi I, Famengo B, d'Amore ESG, Sabattini E, Dei Tos AP. *Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia*. **Br J Haematol**. 2022 Sep;198(5):916-922. doi:10.1111/bjh.18309. Epub 2022 Jun 14.

443. Alessandrini L, Ferrari M, Taboni S, Sbaraglia M, Franz L, Saccardo T, Del Forno BM, Agugiaro F, Frigo AC, Dei Tos AP, Marioni G. *Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens*. **Oral Oncol**. 2022 Sep;132:105982. doi: 10.1016/j.oraloncology.2022.105982. Epub 2022 Jun 24.

444. Campora M, Paudice M, Gambella A, Comandini D, Parente P, Sbaraglia M, Dei Tos AP, Grillo F, Mastracci L. *Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications*. **Virchows Arch**. 2022 Nov 23. doi: 10.1007/s00428-022-03454-w. Epub ahead of print. PMID: 36416965.

445. Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Chs CS, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden 5th, Chacón M, Clara-Altamirano

MA, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati DM, Dufresne A, Eriksson M, Farias-Loza M, Frezza AM, Frisoni T, Garcia-Ortega DY, Gerderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Hindi N, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopes David BB, Lopez-Pousa A, Lutter G, Maki RG, Martinez-Said H, Martinez-Tlahuel JL, Mello CA, Morales Pérez JM, Moura DS, Nakagawa SA, Nascimento AG, Ortiz-Cruz EJ, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Santos TG, Scotlandi K, Mlg S, Soulé T, Stacchiotti S, Valverde CM, Waisberg F, Zamora Estrada E, Martin-Broto J. *Corrigendum to "SELNET clinical practice guidelines for bone sarcoma"* **Critical reviews in oncology/hematology**, vol. 174 (2022), 1-10. *Crit Rev Oncol Hematol*. 2022 Dec;180:103827. doi:10.1016/j.critrevonc.2022.103827. Epub 2022 Oct 8. Erratum for: *Crit Rev Oncol Hematol*. 2022 Jun;174:103685.

446. Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, Zagonel V, Fassan M, Rosato A, Lonardi S. *Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling*. *Front Oncol*. 2022 Dec 8;12:964219. doi: 10.3389/fonc.2022.964219.

447. Bellan E, Zanco F, Baciocchi F, Toffolatti L, Dei Tos AP, Sbaraglia M. *Case report: pseudoendocrine sarcoma, a clinicopathologic report of a newly described soft tissue neoplasm*. *Virchows Arch*. 2022 Dec 23. doi:10.1007/s00428-022-03476-4. Epub ahead of print.

448. Cellini A, Scarmozzino F, Friziero A, Trimarco V, Dei Tos AP, Trentin L, Pizzi M, Visentin A. *Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia*. *Ann Hematol*. 2022 Dec 21. doi: 10.1007/s00277-022-05067-4. Epub ahead of print.

449. Cappellesso R, Nicolè L, Del Fiore P, Barzon L, Sinigaglia A, Riccetti S, Franco R, Zito Marino F, Munari G, Zamuner C, Cavallin F, Sbaraglia M, Galuppini F, Bassetto F, Alaibac M, Chiarion-Sileni V, Piccin L, Benna C, Fassan M, Mocellin S, Dei Tos AP. *TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions*. *Int J Mol Sci*. 2022 Dec 6;23(23):15366. doi: 10.3390/ijms232315366.

450. Del Fiore P, Cavallin F, Mazza M, Benna C, Monico AD, Tadiotto G, Russo I, Ferrazzi B, Tropea S, Buja A, Cozzolino C, Cappellesso R, Nicolè L, Piccin L, Pigozzo J, Chiarion-Sileni V, Vecchiato A, Menin C, Bassetto F, Dei Tos AP, Alaibac M, Mocellin S. *Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features*. *Environ Health*. 2022 Dec 9;21(1):126. doi: 10.1186/s12940-022-00944-x.

451. Bovée JVMG, Webster F, Amary F, Baumhoer D, Bloem JLH, Bridge JA, Cates JMM, de Alava E, Dei Tos AP, Jones KB, Mahar A, Nielsen GP, Righi A, Wagner AJ, Yoshida A, Fletcher CDM. *Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR)*. *Histopathology*. 2022 Dec 4. doi: 10.1111/his.14849. Epub ahead of print.

452. 7. Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium. *Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis*. *Commun Biol*. 2020 Feb 5;3(1):56. doi: 10.1038/s42003-019-0741-7. Erratum in: *Commun Biol*. 2022 Dec 8;5(1):1347. PMID: 32024996; PMCID: PMC7002399.

453. Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium. *Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig*. *Nat Commun*. 2020 Feb 5;11(1):731. doi: 10.1038/s41467-020-14352-7. Erratum in: *Nat Commun*. 2022 Dec 8;13(1):7567. PMID: 32024834; PMCID: PMC7002414.

454. Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium. *Genomic footprints of activated telomere maintenance mechanisms in cancer*. *Nat Commun*. 2020 Feb 5;11(1):733. doi: 10.1038/s41467-019-

13824-9. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7574. PMID: 32024817; PMCID: PMC7002710.

455. Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. *Nat Commun.* 2022 Dec 8;13(1):7571. doi: 10.1038/s41467-022-32343-8. Erratum for: *Nat Commun.* 2020 Feb 5;11(1):734. PMID: 36481739; PMCID: PMC9732291.

456. Cmero M, Yuan K, Ong CS, Schröder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowitz F, Macintyre G; PCAWG Consortium. Inferring structural variant cancer cell fraction. *Nat Commun.* 2020 Feb 5;11(1):730. doi: 10.1038/s41467-020-14351-8. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7568. PMID: 32024845; PMCID: PMC7002525.

457. Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. *Nat Commun.* 2020 Feb 5;11(1):728. doi: 10.1038/s41467-019-13825-8. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7573. PMID: 32024849; PMCID: PMC7002586.

458. Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium. Integrative pathway enrichment analysis of multivariate omics data. *Nat Commun.* 2020 Feb 5;11(1):735. doi: 10.1038/s41467-019-13983-9. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7570. PMID: 32024846; PMCID: PMC7002665.

459. Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. *Nat Commun.* 2020 Feb 5;11(1):736. doi: 10.1038/s41467-019-13885-w. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7572. PMID: 32024823; PMCID: PMC7002524.

460. Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. *Nat Commun.* 2020 Feb 5;11(1):737. doi: 10.1038/s41467-019-14052-x. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7569. PMID: 32024819; PMCID: PMC7002770.

461. Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Iazarugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium. Pathway and network analysis of more than 2500 whole cancer genomes. *Nat Commun.* 2020 Feb 5;11(1):729. doi: 10.1038/s41467-020-14367-0. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7566. PMID: 32024854; PMCID: PMC7002574.

## 2023

462. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium. The repertoire of mutational signatures in human cancer. *Nature.* 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5. Erratum in: *Nature.* 2023 Jan 25;: PMID: 32025018; PMCID: PMC7054213.

463. Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukchim

R, Campbell PJ; PCAWG Consortium. Author Correction: Patterns of somatic structural variation in human cancer genomes. *Nature*. 2023 Jan 25. doi: 10.1038/s41586-022-05597-x. Epub ahead of print. Erratum for: *Nature*. 2020 Feb;578(7793):112-121. PMID: 36697835.

464. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature*. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Jan 25;; PMID: 32025007; PMCID: PMC7025898.

465. Gerstung M, Jolly C, Leshchiner I, Dentre SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhi R, Sahinalp SC, Ji Y, Peifer M, Markowitz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium. The evolutionary history of 2,658 cancers. *Nature*. 2020 Feb;578(7793):122-128. doi: 10.1038/s41586-019-1907-7. Epub 2020 Feb 6. Erratum in: *Nature*. 2023 Jan 25;; PMID: 32025013; PMCID: PMC7054212.

466. Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhyay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uusküla-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, López-Bigas N; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhi R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature*. 2020 Feb;578(7793):102-111. doi: 10.1038/s41586-020-1965-x. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Jan 25;; PMID: 32025015; PMCID: PMC7054214.

467. PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rättsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. Genomic basis for RNA alterations in cancer. *Nature*. 2020 Feb;578(7793):129-136. doi: 10.1038/s41586-020-1970-0. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Jan 25;; PMID: 32025019; PMCID: PMC7054216.

468. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos AP, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hards J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. *Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts*. **Cancer Treat Rev.** 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6.

469. Ruge M, Bricca L, Guzzinati S, Sacchi D, Pizzi M, Savarino E, Farinati F, Zorzi M, Fassan M, Dei Tos AP, Malfertheiner P, Genta RM, Graham DY. *Autoimmune gastritis: long-term natural history in naive Helicobacter pylori-negative patients*. **Gut.** 2023 Jan;72(1):30-38. doi:10.1136/gutjnl-2022-327827. Epub 2022 Jun 30.

470. Hornick JL, Webster F, Dei Tos AP, Hemmings C, Miettinen M, Oda Y, Raut CP, Rubin BP, von Mehren M, Wardelmann E, Fletcher C. *Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)*. **Histopathology**. 2023 Feb;**82(3):376-384**. doi: [10.1111/his.14791](https://doi.org/10.1111/his.14791). Epub 2022 Sep 20.
471. Zannier F, Angerilli V, Spolverato G, Brignola S, Sandonà D, Balistreri M, Sabbadin M, Lonardi S, Bergamo F, Mescoli C, Scarpa M, Bao QR, Dei Tos AP, Pucciarelli S, Urso ELD, Fassan M. Impact of DNA mismatch repair proteins deficiency on number and ratio of lymph nodal metastases in colorectal adenocarcinoma. **Pathol Res Pract**. 2023 Feb 10;**243:154366**. doi: [10.1016/j.prp.2023.154366](https://doi.org/10.1016/j.prp.2023.154366). Epub ahead of print. PMID: 36774759.
472. Quotti Tubi L, Mandato E, Canovas Nunes S, Arjomand A, Zaffino F, Manni S, Casellato A, Macaccaro P, Vitulo N, Zumerle S, Filhol O, Boldyreff B, Siebel CW, Viola A, Valle G, Mainoldi F, Casola S, Cancila V, Gulino A, Tripodo C, Pizzi M, Dei Tos AP, Trentin L, Semenzato G, Piazza F. CK2 $\beta$ -regulated signaling controls B cell differentiation and function. **Front Immunol**. 2023 Jan 11;**13:959138**. doi: [10.3389/fimmu.2022.959138](https://doi.org/10.3389/fimmu.2022.959138). PMID: 36713383; PMCID: PMC9874936.
473. Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, Wardelmann E, Hofer S; Writing committee on behalf of CSSS panellists. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. **Eur J Cancer**. 2023 Feb;**180:158-179**. doi: [10.1016/j.ejca.2022.11.008](https://doi.org/10.1016/j.ejca.2022.11.008). Epub 2022 Nov 16. PMID: 36599184.
474. Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, Zagonel V, Fassan M, Rosato A, Lonardi S. Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling. **Front Oncol**. 2022 Dec 8;**12:964219**. doi: [10.3389/fonc.2022.964219](https://doi.org/10.3389/fonc.2022.964219). PMID: 36578937; PMCID: PMC9791944.
475. Bellan E, Zanco F, Baciocchi F, Toffolatti L, Dei Tos AP, Sbaraglia M. Case report: pseudoendocrine sarcoma, a clinicopathologic report of a newly described soft tissue neoplasm. **Virchows Arch**. 2022 Dec 23. doi: [10.1007/s00428-022-03476-4](https://doi.org/10.1007/s00428-022-03476-4). Epub ahead of print. PMID: 36564514.
476. Cellini A, Scarmozzino F, Friziero A, Trimarco V, Dei Tos AP, Trentin L, Pizzi M, Visentin A. Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia. **Ann Hematol**. 2022 Dec 21. doi: [10.1007/s00277-022-05067-4](https://doi.org/10.1007/s00277-022-05067-4). Epub ahead of print. PMID: 36542103.
477. Marletta S, L'Imperio V, Eccher A, Antonini P, Santonicco N, Girolami I, Dei Tos AP, Sbaraglia M, Pagni F, Brunelli M, Marino A, Scarpa A, Munari E, Fusco N, Pantanowitz L. Artificial intelligence-based tools applied to pathological diagnosis of microbiological diseases. **Pathol Res Pract**. 2023 Feb 6;**243:154362**. doi: [10.1016/j.prp.2023.154362](https://doi.org/10.1016/j.prp.2023.154362). Epub ahead of print. PMID: 36758417.
478. Dei Tos AP, Webster F, Agaimy A, Bovée J, Dickson B, Doyle L, Dry S, Gronchi A, Hameed M, Hemmings C, Liegl-Atzwanger B, Thway K, Wagner AJ, Wang J, Yoshida A, Fletcher C. Datasets for reporting of soft-tissue sarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). **Histopathology**. 2023 Jan 11. doi: [10.1111/his.14862](https://doi.org/10.1111/his.14862). Epub ahead of print. PMID: 36631406.

## Books

1. **Soft Tissue Sarcomas. A pattern based approach to diagnosis.** Dei Tos AP Cambridge University Press, 2019. ISBN 9781316535097



**Chapters in Books**

2. "Patologia e diagnosi dei GIST. In M Lopez (ed) GIST: tumori stromali gastrointestinali." Dei Tos AP, Ninfo V. S. **Editrice Universo Roma, 2005, pp. 15-22**
  
3. "Patologia e diagnosi dei GIST. In M Lopez (ed) GIST: tumori stromali gastrointestinali." Dei Tos AP, Ninfo V. S. **Editrice Universo Roma, 2005, pp. 15-22**
  
4. "Atypical lipomatous tumour/Well-differentiated liposarcoma". Dei Tos AP, Pedetour F. **In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC Press, Lyon, 2002: 35-37.**
  
5. "Dedifferentiated Liposarcoma". Dei Tos AP, Pedetour F. **In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC Press, Lyon, 2002: 38-39.**
  
6. Adipocytic tumors. Dei Tos AP. **In Folpe AL, Inwards CW (eds). Bone and Soft Tissue pathology. Saunders, Philadelphia 2010:97-118.**
  
7. La patologia. Dei Tos AP. **In Comandone A, Barni S (eds) I sarcomi dei Tessuti Molli. Il Pensiero Scientifico Editore Roma 2011: 7-26.**
  
8. Anatomic and Clinical Pathology. De Chiara A, Dei Tos AP, Messina E. **Gastrointestinal Stromal Tumors. Springer Verlag Italia, 2011: 3-14.**
  
9. Istopatologia dei Tumori Rari Licitra L. Olmi P. (Eds) **Tumori della Testa e del Collo Springer Verlag Italia 2011: 47-66.**
  
10. "Atypical lipomatous tumour/Well-differentiated liposarcoma". Dei Tos AP, Pedetour F. **In: WHO Classification of Tumors of Soft Tissue and Bone. IARC, Lyon, 2013: 35-37.**
  
11. "Dedifferentiated Liposarcoma". Dei Tos AP, Pedetour F. **In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC, Lyon, 2013: 38-39.**
  
12. "Adipocytic tumor". L. Laurino, Dei Tos AP, **In: Hornick JL. Practical Soft Tissue Pathology. A diagnostic Approach Elsevier, Philadelphia 2013: 293-321.**
  
13. Gastrointestinal Stromal Tumor. Casali PG, Dei Tos AP, Gronchi A. **In: De Vita V. Cancer. Principle & Practice of Oncology. 10<sup>th</sup> Edition, Walters Kluwer, 2015: 745-756.**
  
14. "Adipocytic tumor". M Sbaraglia, Dei Tos AP, **In: Hornick JL. Practical Soft Tissue Pathology. 2<sup>nd</sup> edition. A diagnostic Approach Elsevier, Philadelphia 2018: 311-340.**
  
15. Gastrointestinal Stromal Tumor. Casali PG, Dei Tos AP, Gronchi A. **In: De Vita V. Cancer. Principle & Practice of Oncology. 11<sup>th</sup> Edition, Walters Kluwer, 2019 .**

**INDICI Bibliografici**

HINDEX SCOPUS: 80

HIMDEX Google Scholar: 95

**Padova, 27/02/23****Prof. Angelo Paolo Dei Tos**

